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Current treatments for cutaneous leishmaniasis suffer from toxic side effects, high
cost, parenteral administration, and drug resistance. Thus, there is a critical need to
develop oral drugs for the treatment of leishmaniasis. OJT007 is a novel class of drug
with potent antiproliferative effects against Leishmania Major. The purpose of this
project is to conduct preclinical drug development studies for OJT007 including
bioanalytical assay development, pre-formulation studies, in vitro hepatic drug
metabolism and in vivo pharmacokinetics.
A sensitive, specific, and reproducible ultra-high performance liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and
validated. The separation was achieved on a UPLC BEH C18 column (2.1 × 50 mm, 1.7
μm) using a mobile phase consisting of 0.1% formic acid in acetonitrile and 0.1% formic
acid in water as gradient elution at a flow rate of 0.4 mL/min. The mass analysis was
performed with a 4000 QTRAP® mass spectrometer using multiple-ion reaction
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monitoring (MRM) in the positive mode, with the transition of m/z 325 → m/z 205 for
OJT007 and m/z 350 → m/z 101 for voriconazole (as internal standard). Rat plasma and
urine were extracted for OJT007 by protein precipitation in acetonitrile for quantification.
Plasma protein binding of OJT007 was determined using the ultrafiltration
method. In vitro phase I and II hepatic metabolism of OJT007 was evaluated in rat liver
microsomes using standard reaction protocols. OJT007 metabolites were identified by
LC-MS/MS using Q1MI, product ion, precursor ion and neutral loss scan and by βglucuronidase hydrolysis. The OJT007 glucuronidation rates were determined by
quantifying OJT007 glucuronide using UPLC, and the kinetic parameters of OJT007
were determined by measuring the initial glucuronidation rates.
. Oral bioavailability of OJT007 was evaluated using a crossover study design.
Serial plasma samples were collected at predetermined time points. Total urine samples
were also collected from each rat for 24 hours after each dose. The pharmacokinetic
parameters were calculated using Phoenix WinNonlin® 8.0 software.
The intra- and inter-day precision and accuracy were within the acceptable limit
of ≤20% for LLOQ and ≤15% for high, medium and low QC. The extraction recovery in
rat plasma and urine samples were 95.1% and 83%, respectively. OJT007 exhibited a
matrix factor in plasma and urine of 7.96% and 12.4%, respectively. The fraction of
OJT007 bound to plasma protein had a mean value of 99.1%, suggesting the drug is
highly bound to plasma proteins.
OJT007 is glucuronidated rapidly in rat liver microsomes to form a monoglucuronide, which was confirmed by LC-MS/MS and β-glucuronidase hydrolysis. The
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kinetic parameters of glucuronidation Vmax and Km were 1.125 nmol/min/mg and 10.73
μM., respectively.
After intravenous administration, OJT007 displayed a bi-exponential disposition
with a rapid distribution followed by a slower elimination. The mean AUC, volume of
distribution, and clearance were 2.06 h.mg/L, 6.90 L/Kg and 2.30 L/hr/Kg, respectively.
Following oral administration, OJT007 was rapidly absorbed with a tmax of 1.4 hours.
After oral dosing the mean AUC, volume of distribution, and clearance were 0.45
h.mg/L, 78.6 L/Kg and 23.19 L/hr/Kg, respectively. Mean oral bioavailability of OJT007
in the co-solvent formulation was 10.9%. The mean percentage of OJT007 dose excreted
unchanged in urine after 24 hours following intravenous and oral administration was less
than 1%, suggesting OJT007 was extensively metabolized in vivo.
A sensitive, specific and reproducible LC-MS/MS method was developed and
validated to quantify OJT007 in rat plasma and urine. The method was successfully used
for pharmacokinetic studies. This is the first time that oral bioavailability of OJT007 after
oral administration in rat is determined. These results may prove valuable for further
preclinical and clinical evaluation of OJT007
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CHAPTER 1
INTRODUCTION
Preclinical studies play a crucial role in the development of new chemical entities
(NCE) and serve as the bridge that connects drug discovery to clinical studies. During
preclinical development a wealth of data on safety and efficacy is amassed for its
potential extrapolation into humans. Undoubtedly, the main goal of drug development is
to understand the pharmacologic response and toxicity of the lead molecule to guide in
the rational design and conduct of clinical studies. In order to accomplish these goals,
typical preclinical development efforts comprehend six major activities:
synthesis/manufacture of the drug substance, safety and toxicology, pharmacology,
manufacture of drug product, method development and validation, pre-formulation and
formulation, metabolism, and pharmacokinetics (Singh, 2018). In this work, we will
focus on the last four activities.
Bioanalytical assay development and validation is a critical prequel to the various
preclinical studies. In fact, the analytical method provides the means to quantitate the
analyte or drug in the relevant biological matrix. Not surprisingly, the FDA recommends
a full validation of any new bioanalytical method (USFDA, 2018). The method validation
is done with the purpose of ensuring the veracity of the data collected during the drug
development studies.

1

2

Maximization of exposure, and thus efficacy, can be accomplished by the
intelligent design of a suitable formulation. The rational design of a formulation entails
pre-formulation studies to assess physicochemical properties of the NCEs to develop a
formulation that will enable in-vivo evaluations. The drug’s physicochemical
characteristics and the intended route of administration are key driving factors in the
formulation of an NCE.
Pharmacokinetics studies what the body does to a drug. It encompasses four basic
processes: absorption, distribution, metabolism, and excretion of a drug. Early
characterization of each of these processes enables the selection of the best candidates for
further development. An important byproduct of pharmacokinetic evaluations is that the
information accumulated can be used to predict plasma concentrations, target dose, and
the fate of the administered dose.
Part of a drug’s pharmacokinetic evaluation comprehends an assessment of drug
metabolism. Drug metabolism is a significant determinant of a drug’s clearance since
generally drugs undergo biotransformation for its elimination. The ultimate purpose of a
preclinical metabolism assessment is to predict the behavior of a drug in humans and to
ensure safe clinical studies. In addition, early in drug development, drug metabolism
studies can help select drugs more likely to have appropriate exposure in vivo by
identifying drugs which are resistant to extensive metabolism.
In this work, we aimed to apply the guiding principles of pharmacokinetics for the
rational development of a novel antileishmanial agent. The treatment of leishmaniasis
relies on drugs that suffer from toxic effects, high costs, mixed efficacy, and parenteral
administration. Notwithstanding the need for R&D of drugs for CL, the pipeline remains
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poor (Golgher et al., 2011). Recently, OJT007 was identified as a potent and selective
methionine aminopeptidase inhibitor against L.major. Furthermore, the compound
demonstrated efficacy in vivo following oral administration with no toxicity (Rodriguez
et al., 2020). The dearth of oral chemotherapeutic agents for CL and the promising in vivo
results makes OJT007 an attractive candidate for further development.
In this dissertation, we seek to evaluate the feasibility of OJT007 as a novel
chemotherapeutic candidate. Accordingly, the development and validation of a
bioanalytical assay for the quantification of OJT007 in urine and plasma is reported. The
results of pre-formulation studies to characterize physicochemical properties of OJT007
and its application to the development of a cosolvent are outlined. The in vitro
metabolism of OJT007 in rat liver microsomes is investigated. The bioanalytical method
and formulation were applied to investigate the pharmacokinetics of OJT007 in rats.

CHAPTER 2
LITERATURE REVIEW
2.1 Leishmania Species and Leishmaniasis
Leishmaniases are vector-borne parasitic diseases caused by more than 20
Leishmania species and are spread to humans by over 90 species of infected sand flies.
About 12 million people suffer from leishmaniasis (Mohammadi & Soltani, 2019).The
disease is endemic across all continents except Australia and affects the most vulnerable
populations. Some risk factors associated with the disease include poverty, poor housing
and domestic sanitary conditions, malnutrition, and immunosuppression (Burza et al.,
2018).
Though tropical areas are more prone to leishmaniasis infection, migration and
travel have put at risk previously unaffected populations. As a result, leishmaniasis is an
emerging concern in the United States with authors reporting non-endemic and endemic
infections. (Barry et al., 2014; McIlwee et al., 2018; Wortmann et al., 2002; Wright et al.,
2008)
There are different forms of leishmaniasis in people: Cutaneous leishmaniasis,
visceral leishmaniasis and mucocutaneous leishmaniasis. Visceral Leishmaniasis (VL), or
Kala-azar, is one of the deadliest diseases among the neglected tropical diseases if left
untreated (Pandey et al., 2020). Depending on the transmission characteristics, VL is

4

5

classified as zoonotic or anthroponotic. The zoonotic form, which is caused by L.
infantum, uses dogs as main reservoir, and generally affects children and
immunocompromised individuals. The anthroponotic form, which is caused by L.
donovani and L. chagasi, is more common and affects all age groups. (van Griensven &
Diro, 2012). Clinical manifestations consist of fever, malaise, weight loss, hepatomegaly,
splenomegaly and pancytopenia (Pearson & Sousa, 1996). Visceral leishmaniasis has an
incidence of 50000 to 90000 cases per year worldwide with the majority of the cases
occurring in Brazil, Ethiopia, Eritrea, India, Iraq, Kenya, Nepal, Somalia and Sudan.
(World Health Organization, 2021).
Cutaneous Leishmaniasis (CL) is the most common form of leishmaniasis. It is
characterized by skin lesions, mainly ulcers, on exposed body parts. An estimated
600,000 to 1 million cases occur worldwide annually (World Health Organization, 2021).
Approximately 66,941 patients of CL are reported annually in the Americas which
accounts for approximately 30% of the total patients of CL worldwide (Pan American
Health Organization, 2018).
Mucocutaneous Leishmaniasis (MCL), a sequela of infection with CL, leads to
partial or complete destruction of the mucosal membranes of the nose, mouth and throat.
Approximately a few thousand cases occur worldwide each year (Karunaweera et al.,
2020).
The causative agents for CL have been classified as ‘Old World’ and ‘New
World’. In Africa and Eurasia (‘Old World’), leishmaniasis is generally caused by L.
major, L. tropica, L. aethiopica, L. infantum, and L. archibaldi. In the Americas or ‘New
World’ leishmaniasis is caused by L. mexicana, L. venezuelensis, L. amazonensis, L.
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braziliensis, L. panamensis, L. chagasi, L. guyanensis, and L. peruviana. (Akilov et al.,
2007)
2.1.1. Parasite life cycle
Figure 1 summarizes the life cycle of Leishmania. Leishmania parasites have two
major cell morphologies: the promastigote which is characterized by a long motile
flagellum, and the amastigote which is characterized by a short immotile flagellum.
Leishmania infected sand flies inoculate the promastigote stage of the parasite during
blood meals. The promastigotes at the puncture site are phagocytized by macrophages,
monocytes, and neutrophils. Once inside the macrophage the promastigotes differentiate
into the amastigote stage, proliferate by simple division, and proceed to infect other cells
and tissues. During a blood meal, the sand fly ingests the amastigote stage of the parasite,
which then begins to differentiate into the motile promastigote form (Séguin &
Descoteaux, 2016; Sunter & Gull, 2017).
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Figure 1. Leishmania Life Cycle,
Center for Disease Control and Prevention,2021. Leishmaniasis Biology. Retrieved from
CDC - Leishmaniasis - Biology
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2.1.2 Vectors and transmission
The Leishmaniases are transmitted by the bite of small, hairy, soundless, and
blood-feeding insects named sand flies. Vectors in the ‘Old World’ and ‘New World’
belong to the genus Phlebotomus and Lutzomyia, respectively. Pheblotomus sandfly
species live in semi-arid ecosystems or deserts while Lutzomyia sandflies live in forests
(Sharma & Singh, 2008). Transmission is both anthroponotic or zoonotic, and it depends
on whether human is the main reservoir (Reithinger et al., 2007).
2.2 Cutaneous leishmaniasis (CL)
2.2.1 Clinical manifestations
The clinical manifestations of the disease are the product of the complex
interaction between the parasite virulence characteristics, vector biology, and host factors
(i.e., immune response). Intracellular infection of dermal macrophages by Leishmania
parasites causes an excessive host immune response leading to tissue damage and disease
(Wijnant et al., 2018). The varied clinical forms include localized cutaneous lesions,
disseminated cutaneous lesions, and mucosal lesions.
In simple, localized, uncomplicated localized cutaneous leishmaniasis (LCL), the
first sign of an infection is typically a small erythema that develops into a red papule at
the site where sandfly bit the host. The papule slowly evolves into a firm nodule with an
iceberg configuration. The nodule enlarges and ulcerates into a lesion that resembles a
flattened volcano (Figure 2, Panel A). Ulcerative lesions generally self-heal 5-12 months
after initial appearance leaving cribriform scars. Secondary bacterial infections are
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possible, especially in ulcerated lesions, which exacerbate the symptoms of leishmaniasis
(Akilov et al., 2007).
The appearance of disseminated cutaneous leishmaniasis (DCL) was first
described in Venezuela in 1948 (Convit & Lapenta,1948). It is caused by L. aethiopica in
the ‘Old World’ and by L.amazonensis in the ‘New World’(Vélez et al., 2015). DCL may
occur due to the parasite’s ability to migrate via the lymph or blood to different areas of
the body (Figure 2, Panel B). Lesions in DCL are mostly papules and nodules that do not
ulcerate. DCL is more serious than LCL due to an inhibition of specific cellular immunity
(Vélez et al., 2015).
Mucocutaneous Leishmaniasis (MCL), occurs as a sequela of CL infection,
though it can co-occur. Inadequate therapy of LCL is a risk factor for MCL. In the New
World, it is caused by L. braziliensis , although L. panamensis , L. guyanensis , and L.
amazonensis can also be involved. In the Old World, it is caused by L, major and
viscerotropic L. infantum (Goto & Lauletta Lindoso, 2012). The symptoms associated
with MCL include nasal inflammation, ulceration, and perforation of the septum (Figure
2,Panel C). In occasions, the lesions may extend, and parts of the face, soft palate,
pharynx, and larynx may be affected (Goto & Lindoso, 2010).
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Figure 2. Cutaneous leishmaniasis clinical manifestations. A) Localized lesions. B)
Disseminated lesions. C) Mucocutaneous lesions.
Adapted from “Cutaneous Leishmaniasis” by R. Reithinger et al. 2007
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2.3 Current treatment of CL
Generally, CL lesions self-heal without treatment; however, self-healing may take
several months and can leave disfiguring scars (Scorza et al., 2017). Therapeutic
interventions are used in order to accelerate cure and to prevent scarring and
mucocutaneous disease. Due to the heterogeneity of the causative infectious agent, there
is no universal treatment for leishmaniasis (Minodier & Parola, 2007). Pharmacological
treatment options can be local or systemic.
2.3.1 Local chemotherapeutics
Local treatments are the treatment of choice in Old World Leishmaniasis, while
for New World CL, systemic treatments are preferred because of the risk of developing
MCL. Drug administration through the skin is particularly appealing as it could deliver
doses of the drug to the target while preventing adverse effects due to the drug acting off
target.(Khalil et al., 2019)
2.3.1.1 Paromomycin Sulfate
Aminoglycosides inhibit bacterial protein biosynthesis (van Hees & Naafs, 2016).
Paromomycin topical treatment has displayed mixed efficacy and modest benefits. Skin
permeation is an important problem limiting the efficacy of topical paromomycin (Khalil
et al., 2019). Paromomycin 15% with methylbenzethonium 12% was effective for 72%
of the patients as therapy for L. major infection in Israel (El-On et al., 1986). In a study in
Colombia that treated patients with topical 15% paromomycin plus 0.5% gentamicin cure
rates were similar to those obtained in placebo. Nonetheless, it appeared that cure time
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was faster in patients treated with paromomycin (J. M. Soto et al., 2002). Local irritation
has been the most common side effect associated with paromomycin use.
2.3.1.2 Intralesional pentavalent antimony
Intralesional pentavalent antimony is widely used in the treatment of Old World
and New World CL. It is applied alone or in combination with cryotherapy. The basic
aim of local infiltration is to fill infected parts in the dermis with the drug, making sure
not to inject onto the subcutaneous tissue, as this would prevent the drug from reaching
the site of action (van Hees & Naafs, 2016). Pentavalent antimony is recommended for
simple CL cases where lesions do not involve face of joints (Vera et al., 2021).
Intralesional administration results advantageous because a high concentration of the
Sb(V) can be delivered into the diseased tissue, which would be toxic if treated
systemically (Oliveira-Neto et al., 1997).
2.3.2 Systemic chemotherapeutics
Systemic chemotherapeutics include parenteral treatments, mainly intravenous
(IV) or intramuscular (IM), and oral treatments.
2.3.2.1. Pentavalent antimonial (IV, IM)
Pentavalent antimonial (Sb(V)) compounds such as sodium stibogluconate
(Pentostam) and meglumine antimoniate (Glucantime) are the first-line drugs in the
treatment of leishmaniasis. The mechanism of action of Sb(V) is not entirely understood,
though it seems to involve inhibition of macromolecular biosynthesis in amastigotes via
perturbation of energy metabolism (van Hees & Naafs, 2016). Pentavalent antimony is
given as an intramuscular or intravenous injection in a dose of 20 mg/kg/day for up to 30
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days. Sb(V) has a cure rate of 90% when it is used at an appropriate dose (Thakur et al.,
1988). Nonetheless, the appropriate dose and duration of treatment have changed over the
course of years to prevent therapeutic failure caused by antimony resistance (Ryan &
Magill, 2020).
The use of pentavalent antimonial is often accompanied by severe side effects
such as cardiotoxicity, hepatotoxicity, nephrotoxicity, and pancreatitis (Kato et al., 2014).
Furthermore, these side effects have been exacerbated by the increased dose and length of
treatment necessary for maintaining the cure rate. For instance, QT prolongation has been
observed in patients treated with Sb(V) and this prolongation in the QT interval appears
to be directly related to the dose administered (Ryan & Magill, 2020).
2.3.2.2. Amphotericin B (IV)
Conventional Amphotericin B (Amphotericin B deoxycholate) is a polyene
antibiotic used in systemic fungal infections. It is used as a second-line treatment for
mucosal or localized cutaneous leishmaniasis, especially with pentavalent antimony
treatment failure. The dose of amphotericin B is 1 mg/Kg/day infused over two hours
every other day up to 30 days (Sundar & Chakravarty, 2013). The drug binds to
leishmania parasites’ membrane sterol (ergosterol), creating pores that lead to cell death.
Nonetheless, because mammalian and leishmanial membranes contain sterols,
amphotericin B causes toxicity in humans by binding to cholesterol. Although the activity
of amphotericin B is higher against ergosterol than cholesterol, it can cause serious side
effects against the host, such as nephrotoxicity, hypokalemia, and myocarditis (Eriksson,
2001).
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The various side effects are minimized by using lipid formulations that decrease
the free drug’s exposure to organs. Short courses of liposomal amphotericin B at a dose
of 3-4 mg/kg/day on days 1-5 and a sixth dose on day 10 have shown to be effective
(Solomon et al., 2011). Liposomal amphotericin B has been shown to be less nephrotoxic
because it is selectively taken up by macrophages, the Leishmania parasite target cell
(Solomon et al., 2011). Although toxicity is minimized in liposomal amphotericin B, high
cost becomes a significant problem in developing countries (Sundar et al., 2001).
2.3.2.3. Pentamidine (IV, IM)
Pentamidine isethionate is a diamidine drug. Its mechanism of action is not
entirely understood, but it appears to interfere with DNA synthesis and modify the
morphology of kinetoplast (Kaur & Rajput, 2014). It is the drug of choice for the
treatment of cutaneous leishmaniasis caused by infection with L. guayanensis and L.
panamensis (Soto-Mancipe et al., 1993; van Hees & Naafs, 2016). Three or four 4 mg/Kg
injections every other day are well tolerated via IV infusion or deep IM injection.
Toxicity seems to be dose-related and includes adverse effects such as hypotension,
phlebitis, permanent diabetes mellitus, nephrotoxic effects, arrhythmia, and mild cardiac
toxicity (Piccica et al., 2021).
2.3.2.4 Paromomycin
Paromomycin is an aminoglycoside that binds to 16S ribosomes RNA and inhibits
protein synthesis. Systemic use of paromomycin for cutaneous leishmaniasis is rare due
to mixed efficacies depending on the causative infectious species. For instance, a dose of
20 mg/Kg/day for 20 days was shown efficacious in infection caused by L. braziliensis
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(Correia et al., 1996); However, L. panamensis showed resistance and efficacy was
insubstantial (J. Soto et al., 1994). In addition, side effects such as ototoxicity and
nephrotoxicity limit its use to treat CL.
2.3.2.5 Azoles (PO)
The antifungals ketoconazole, fluconazole, and itraconazole have shown variable
results in the treatment of leishmaniasis. Their mechanism of action is inhibition of
lanosterol 14-α-demethylase, which blocks the formation of ergosterol, a fundamental
component of the cell membrane (Ghannoum & Rice, 1999).
A dose of 400 mg daily for 28 days was found efficacious in treating cutaneous
leishmaniasis caused by L. major. Reported adverse effects are mild and limited to
reversible abnormalities in hepatocellular function test and decreased serum testosterone
values (Saenz et al., 1990; Weinrauch et al., 1983). Oral fluconazole at a dose of 5
mg/Kg/day for 12 days has been shown efficacious against disseminated cutaneous
leishmaniasis in Venezuela, and the merits of this treatment deserve future studies (Daly
et al., 2014). Itraconazole has shown merits in the treatment of mucosal leishmaniasis due
to its better bioavailability and ability to achieve higher exposure in tissue and mucosa.
For instance, itraconazole displays 65% and 51% efficacy in localized cutaneous
leishmaniasis and mucocutaneous leishmaniasis, respectively (Galvão et al., 2017).
2.3.2.6 Miltefosine (PO)
An alkyl phospholipid, initially developed as an oral antineoplastic agent, inhibits
phospholipid and sterol biosynthesis (van Hees & Naafs, 2016). It is the only oral
treatment of leishmaniasis approved by the FDA. The FDA regimen is 2.5 mg/kg/day

16

with a maximum dose of 150 mg/day. Miltefosine displays mixed efficacy, with high
variability between countries and leishmania species (Garza-Tovar et al., 2020). The
reported cure rates range from 50% (L. braziliensis and L. Mexicana in Guatemala) to
88% (L. panamensis in Colombia)(J. Soto et al., 2004). Likewise, miltefosine has shown
a modest efficacy of 65% against CL infection caused by L. tropica (J. Soto et al., 2004).
Even within same species, efficacy variations have been observed (J. Soto et al.,
2007). The drug non susceptibility of certain leishmania species to miltefosine has been
associated with low expression of the putative L. donovani miltefosine transporter
(LdMT) and the protein LdRos3 both of which aid in drug internalization into the parasite
(Dorlo et al., 2012). Of particular concern is that miltefosine has a long half-life, this
leads to subtherapeutic levels of miltefosine in blood for several weeks and could
potentially cause drug resistance (Dorlo et al., 2008). The toxicity associated with
miltefosine treatment is mild, including adverse effects such as vomiting and diarrhea,
which occur in a dose-dependent matter (Machado & Penna, 2012).
2.4 Drug discovery and development in CL
Clinical drug development is a costly and lengthy process. The cost to develop
New Chemical Entities (NCE) is around 2.6 billion (Mohs & Greig, 2017) . Preclinical
drug discovery and development aims to deliver candidate molecules that have
appropriate efficacy at target site, safety and drug-like properties. Approximately 63% of
all preclinical compounds nominated for clinical development fail due to poor
pharmacokinetics and toxicity (Han et al., 2010). Nonetheless, the discovery and
development of new antileishmanial agents remains a commercially unattractive area of
R&D; thus, it has been explored primarily in the realm of academic research.
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2.4.1 Methionine aminopeptidase as a target for infectious disease
Methionine aminopeptidase (MetAP) is a metalloprotease that catalyzes Nterminal methionine cleavage from proteins during translation. Protein synthesis is
initiated with a formylated methionine in prokaryotes or methionine in eukaryotes.
Methionine is usually removed from mature proteins in eukaryotes by MetAP
(Methionine aminopeptidase). In prokaryotes , formyl methionine is removed by formyl
methionine deformylase resulting in N-terminal methionine, which MetAP.then processes
(O. A. Olaleye et al., 2009).
There are two types of MetAPs, 1 and 2; prokaryotes have homologs of either
type, while eukaryotes have both (O. A. Olaleye et al., 2009). Nonetheless, eukaryotes
develop lethal phenotypes if either MetAP gene is deleted (X. Li & Chang, 1995). Nterminal excision (NME) is necessary for post-translational modifications, stability,
folding, and the localization of nascent proteins. The essentiality of NME in eukaryotes
and prokaryotes makes it a promising target for infectious diseases. Various types of
MetAP have been validated as targets for a variety of infectious diseases caused
by Mycobacterium Tuberculosis (Mtb, the causative agent of TB) (O. Olaleye et al.,
2010), Plasmodium falciparum (the causative agent of malaria)(Gardiner et al.,
2009), Acinetobacter baumannii (a Gram-negative bacillus resistant to most of the
antibiotics in use) (Yuan et al., 2011)and Cryptosporidium parvum (a parasite that infects
epithelial cells and causes diarrhea)(Kang et al., 2012). Recently, MetAP1 inhibitors have
shown promising results against Leishmania donovani, giving evidence for the use of
MetAP1 inhibitors for the treatment of Leishmaniasis (Bhat et al., 2018).

18

2.4.2 Identification of OJT007 as a methionine aminopeptidase inhibitor.
The identification used a target-based approach. Briefly, a high-throughput screen
of 175,000 structurally diverse compounds against MetAP1 was conducted. A total of
439 hits that exhibited 30-40% inhibition were identified. The IC50 was determined for 81
compounds. The most potent inhibitors were then tested on the growth of M. tuberculosis
culture. This effort led to the discovery of eight potent MetAP1 inhibitors against M.
tuberculosis (O. Olaleye et al., 2010, 2011).
2.4.3 Identification and characterization of OJT007 as a treatment for Cutaneous
Leishmaniasis caused by L. major.
As part of the drive to find new antileishmanial treatments, the antiparasitic
activity of these eight novel MetAP1 inhibitors against CL infection caused by L. major
was screened and characterized. The screen led to the identification of OJT007, a
MetAP1 inhibitor with potent and selective leishmanicidal activity against L. major
(Rodriguez et al., 2020).
OJT007 displayed an EC50 of 500nM against L.major promastigotes and
amastigotes with no cytotoxicity to hosts cells. Furthermore, the drug demonstrated oral
efficacy in a preclinical mouse model. In a BALB/c animal mode, OJT007 decreased
parasite load and decreased lesion size. In addition, it did not generate changes in weight,
nor did it cause cardiac or hepatic damage. These promising results made OJT007 an
attractive candidate for the oral treatment of cutaneous leishmaniasis (Rodriguez et al.,
2020).
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2.5 OJT007
OJT007 is known by the IUPAC as 2-[(E)-(5,6,7,8-tetrahydro-[1] benzothiolo
[2,3-d]pyrimidin-4-ylhydrazinylidene)methyl] phenol. It has a molecular formula of
C17H16N4OS, and a calculated molecular weight of 324.4 g/mol (Figure 3). OJT007
occurs as yellow fine needle-like crystals with no noticeable odor and unknown taste. The
studies reported in this work were conducted using the free base of OJT007.
2.5.1 Physicochemical characteristics of OJT007
The calculated physicochemical properties of a drug are paramount in identifying
the most druggable lead during drug discovery and development. Furthermore, these
properties serve as early predictors of orally active drugs. As we will learn in the
following section, the physicochemical properties of a drug affect the drug permeability
and solubility, which consequently affects drug absorption.
The physicochemical properties of OJT007 were obtained using the American
Chemical Society (ACS) database, SciFinder®. These properties are summarized in
Table 1. OJT007 is a lipophilic compound, suggesting that the compound shows
preference to be associated with lipid phase and, by extension, will likely permeate
biological membranes easily by passive diffusion.
OJT007 has a calculated water solubility of 8.1 μg/ml, making OJT007 sparingly
soluble in water. Low water solubility may have important implications in drug
absorption. Solubility of the drug is a prequel to permeation across the GI tract. Thus,
solubility may become a limiting factor in the absorption process. The calculated melting
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point for OJT007 is 200OC. High melting points have been associated with poor
solubility due to the strong cohesive forces between molecules (Semalty, 2014).
The drug is amphoteric; it has three calculated ionizable groups, two basic, and
one acidic pKa. At physiological pH, the drug would be primarily unionized. The pH
range found in the gastrointestinal tract from the stomach to the colon is about 1-8. The
very weakly acid ionizable group in OJT007 (pKa 8.7) would theoretically be unionized
across the GI tract. On the other hand, the weakly basic amine (pKa -2.2) would
theoretically be unionized across the GI tract, while the basic amine (pKa 5.8) would be
primarily ionized at low pH (i.e., fasting conditions pH) and unionized in the intestines.
2.6 Physicochemical characteristics of successful oral drugs
Oral efficacy is dependent on potency and oral bioavailability. An important
distinction must be made between absorption and bioavailability. Absorption refers to the
drug penetration across the intestinal membrane. On the other hand, bioavailability refers
to the appearance of unaltered drug in the systemic circulation (beyond the liver).
Physicochemical characteristics, and the characteristics of the environment in the GI
tract, affect the inherent absorbability and the bioavailability of a drug.
In a retrospective analysis, Christopher Lipinski analyzed a database of 50,000
compounds. A subset of over 2245 compounds that had entered Phase II were selected
under the hypothesis that those compounds with poor physicochemical properties would
fail preclinical and phase I evaluation. An analysis of the physicochemical properties of
these compounds yielded several observations: 11% of the 2245 compounds had a
molecular weight above 500 Da. Approximately 10% of the compounds had a calculated
log P <5. High log P are associated with low solubility.
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Figure 3. Chemical structure of OJT007
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Table 1. Calculated Physicochemical Properties of OJT007
Property

Value

Condition

Density

1.46 g/cm3

Temp: 20 °C Press: 760 Torr

Melting point

200.5

-

Log P

4.89

Temp: 25oC

Solubility

-4.6 (8.1 μg/ml)

Temp: 25oC
pH=7.0

pKa

8.7±0.3

Most Acidic Temp: 25oC

5.8±0.2

Most Basic Temp: 25oC

*Calculated using Advanced Chemistry Development (ACD/Labs) Software v11.02 (© 1994-2020
ACD/Labs
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In addition, 8% of the molecules had more than 5 hydrogen bond (H-bond) donor groups
(i.e., NH or OH).12% of the compounds had more than 10 H-bond acceptors atoms.
(Lipinski et al., 1997)
This analysis led to the rule of five, which has helped pharmaceutical scientists reach
early decision regarding developability of drug candidates across the years. The `Rule of
Five' (RO5) states that poor absorption is more likely when a compound possesses:
•

ClogP greater than five

•

Molecular mass over 500 Da.

•

More than five H-bond donors (sum of Nitrogen and Oxygen attached to one or
more hydrogen atoms)

•

More than ten H-bond acceptors (sum of Nitrogen and Oxygen)

Oral bioavailability (Figure 4) is a function of the fraction absorbed by the gut wall
(Fa), Fraction escaping intestinal metabolism (Fg) and fraction escaping hepatic
metabolism (Fh) (Equation 1). Fa is a function of the drug solubility, intrinsic
permeability of the drug, GI stability. Fg is affected by active efflux into the intestinal
lumen and by intestinal wall metabolism. Fh is a function of metabolism and transport.
F= Fa x Fg x Fh

(1)

The biological membranes lining the GI tract is described as a phospholipid
bilayer interrupted by water pores; Thus, enabling lipid soluble molecules to readily
penetrate the lipid region while small water soluble molecule cross through the aqueous
channels (Song et al., 2004). In general, membrane permeability increases with an

24

increased Log P; This is because the attractive forces between drug-membrane
interactions are greater than the attractive force between drug-solvent (Mayersohn, 2002).
Although a high log P is good for passive membrane permeability, values that are
too high (>6 log P) may indicate poor aqueous solubility (since the drug preferentially
associates in lipophilic regions) which in turn can cause poor absorption. Likewise, they
may indicate the compound is susceptible to metabolism and biliary clearance.
High molecular weight of compounds (>500) has been associated with a
decreased passive diffusion. Likewise, high molecular weight compounds may be
associated with low solubility, an important prequel to membrane permeability(Navia &
Chaturvedi, 1996). The hydrogen bonding ability of a drug is used as an estimate of its
hydrophilicity. In this way, both hydrogen bond acceptor and donor atoms are associated
with decreased drug permeability (Song et al., 2004).
2.6.1

Drug likeness of OJT007
Lipinski’s rule of five is informative in early decision-making regarding drug

candidates at early stage. OJT007 meets all the criteria of the RO5 (Table 2) suggesting
that the molecule is likely to be active when administered orally to humans. Nonetheless,
this should be interpreted with caution as these predictions do not always equate to
success in experimental models. This phenomenon may be attributed to, among other
things, the RO5 missing to consider important disposition factors such as the involvement
of transporter (C.-Y. Wu & Benet, 2005).
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Table 2: Lipinski Properties of OJT007
Property

Predicted Value

Molecular Weight

324.4 g/mol

Hydrogen bond acceptors

5

Hydrogen bond donors

2

Calculated log P (Clog P)

4.89

*Calculated using Advanced Chemistry Development (ACD/Labs) Software v11.02 (© 1994-2020
ACD/Labs

27

2.7 Bioanalytical Assay Development
Bioanalytical assay development plays an essential role in drug development. The
ability to quantitate the parent drug and/or metabolite in the relevant biological matrices
is a prerequisite to conduct robust pharmacokinetic, toxicokinetic and pk/pd studies. An
important feature of bioanalysis in drug development is the need for quantification at
very low concentrations levels: in the ng/ml or even pg/ml concentration range. LCMS/MS has become the standard instrument for bioanalytical quantification replacing
other analytical techniques such as HPLC and GC (Abdel-Hamid, 2000).
LC-MS/MS has several advantages over UPLC-UV. Classical UPLC methods
rely on the UV absorbing properties of a drug. For drugs with weak UV absorbing
properties, quantification at low concentration is problematic. In LC-MS/MS, detection
relies on monitoring the specific mass of the molecular or fragment ion which results in
higher sensitivity and specificity.
The LC-MS/MS offers greater sensitivity and specificity; however, there are
limitations to its use. The electrospray ionization source is highly susceptible to
contaminants. Furthermore, nonvolatile buffers are not amenable for LC-MS/MS
analysis. Even low concentrations of nonvolatile buffers in the LC-MS/MS can cause
severe signal suppression (Sterling et al., 2010). In addition, excipients such as PEG 400
and Tween 80 are not amenable for direct quantification in LC-MS/MS (Temesi et al.,
2003). The signal suppression phenomenon is observed due to a competition in the
ionization process between the analyte of interest and the contaminant (Choi et al., 2001).
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2.7.1 Quantification without a reference standard
New chemical entities seldom have commercially available authentic standards
for their metabolites. This situation becomes an important hurdle in enzyme kinetic
studies because, ideally, all quantification must be conducted against a reference
standard. Overcoming this difficulty using LC-MS/MS is not advisable. The addition of
polar ionizable groups like glucuronides during metabolism dramatically impacts the
molecule’s ionization resulting in an over or underestimation of metabolism. (Blanz et
al., 2017)
Quantification of metabolite by LC-UV is a more sensible approach. Each
compound has an extinction coefficient. Extinction coefficients are a function of its
chemical moieties or chromophores. If these structural motifs do not change significantly
in the metabolite compared to the parent molecule, it is reasonable to assume that the
metabolite’s extinction coefficient has not changed. In this case, metabolite
concentrations can be compared to the parent molecule using the standard curve built for
the parent molecule. On the other hand, stark changes in λmax would indicate that
quantification cannot be performed without having an authentic standard (Y. Li et al.,
2014).
Many studies assume that molar extinction coefficients remain the same as their
corresponding parent; therefore, quantification was accomplished in each of those cases
using the calibration curve of the parent drug (P. Li et al., 2015). More precise
estimations can be accomplished by determining the conversion factor (K), which is the
ratio between the molar extinction coefficient of the metabolite and the parent drug. (Gao
et al., 2011; Zhang et al., 2006)
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According to Beer-Lambert Law
A=ε x C

(2)

Where A, ε and C are the UV absorbance, molar extinction coefficient and the
concentration of absorbing species, respectively. At equal molar concentration, the
following equality can be established Ap/εp= Am/εm. Where Ap, Am represent the UV
absorbance of parent and metabolite, while

εp and εm represent the molar extinction

coefficient of parent and metabolite, respectively. If we assume 1 mole of OJT007
generates 1 mol of glucuronide during glucuronidation, then Am and Ap can be
represented as ΔOJT007Glu and ΔOJT007, where ΔOJT007Glu is the peak area change for OJT007
Glucuronide and ΔOJT007 is the peak area change for OJT007. Thus, a conversion factor
K= ΔOJT007Glu / ΔOJT007=Am/Ap= εm / εp can be established in the study. The metabolite
concentration can be established by using the conversion factor K and the parent standard
curve (Zhang et al., 2006).
2.7.2 Method Validation
Validation of bioanalytical methods helps to ensure the reliability of the obtained
results. Likewise, validation covers the steps pertinent to PK studies, including sample
collection, handling, storage, and preparation. The U.S. FDA recommends that all
methods be validated for standard (calibration) curve, selectivity, accuracy and precision,
stability under normal storage and handling conditions, extraction recovery and matrix
effect, and dilution integrity (USFDA, 2018). A summary of the validation parameters is
shown in figure 5.
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Sensitivity refers to the lowest concentration that can be accurately and precisely
quantitated (i.e., LLOQ). The calibration curve is defined as the relationship between
instrument response and the known calibrators concentration within an intended
quantitation range. As per guidance, it should consist of a blank (matrix sample without
IS), a zero calibrator (matrix sample processed with IS), and at least six standards
covering the expected range including the LLOQ.
Selectivity refers to the ability to determine and unambiguously assess an analyte
in the presence of all expected matrix components (Tiwari & Tiwari, 2010). Accuracy is
the closeness of the measured value to the nominal concentration. It is typically measured
as relative error (%RE) (Deshpande et al., 2019). Precision reflects the closeness of
agreement of individual samples run multiple times under the same operating conditions
expressed as percentage coefficient of variation (CV%) (Tiwari & Tiwari, 2010).
The percentage recovery refers to the extraction efficiency, reported as response
obtained from an extracted sample to the results obtained by analyzing unextracted
samples. The primary purpose of extraction is removing the proteins and interfering
substances to assist in chromatographic separation, minimizing matrix effect during
ionization in MS, and increasing sensitivity. Although recovery does not need to be
100%, the agency highlights it is important for recovery percentage to be consistent and
reproducible across concentrations (USFDA, 2018). The Matrix effect is the suppression
or enhancement of analyte ionization due to the presence of unintended analytes or
interfering substances in the sample.
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Figure 5. Validation Parameters FDA
From “Bioanalytical Method Validation: an updated review” by Tiwari et al. 2010
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2.8 Formulation for preclinical studies
2.8.1 Pre-formulation studies
The use of high-throughput screening and combinatorial chemistry during drug
discovery has resulted in new chemical entities characterized by low water solubility.
Consequently, the preparation of suitable formulation for in vivo studies is a significant
hurdle in drug development. Investigational new drug (IND) applications require a
description of the physical and chemical characteristics of the NCE (USFDA, 2006). The
typical pre-formulation studies include physicochemical characterization of the solid and
solution properties of a drug with the purpose of amassing pharmaceutical information
that would be useful in the development of a suitable delivery system. Some of the preformulation studies consist of pKa, solubility, stability tests, log P, melting point (Niazi,
2019)
2.8.2 Cosolvent Formulation
In the early stages of drug development, solution dosage forms offer the important
advantage of minimizing dissolution limited absorption. Several techniques can be used
to solubilize poorly water-soluble molecules: pH manipulations (acid or base drugs),
cyclodextrin complexations, cosolvents. PH manipulation techniques suffer from
precipitation upon dilution after dosing; Likewise, in occasions, the pH for optimal
solubility is extreme and could potentially cause side effects (Bosselmann & Williams,
2012). Inclusion complexes may not achieve the desired solubility, especially because of
the drug conformations constraints for successful complexation (Davis & Brewster,
2004). Cosolvents result attractive due to their dramatic increase in solubility and their
simplicity.
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Cosolvency is a common approach to improve the solubility of poorly watersoluble drugs. Cosolvents are a mixture of miscible solvents that increase a nonpolar
molecule’s water solubility. The mechanism by which cosolvents achieve this task is by
reducing the surface tension between the water and hydrophobic solute. Many of the
water-miscible solvents used in cosolvent formulations are toxic; because of this, the
following criteria must be met during formulation: nontoxicity, compatibility with blood,
non-sensitizing, physically and chemically stable and inert.
Following this further, during formulation excipients must be selected carefully
especially since formulation vehicles may have effects on pharmacokinetic studies due to
their ability to affect metabolic enzymes, transporters, and distribution. (Trivedi & Yue,
2017)
2.9. Pharmacokinetics Studies
2.9.1 Role of pharmacokinetics in preclinical drug discovery and development
One of the main reasons drugs fail during clinical development is unsatisfactory
pk/bioavailability or toxicity. Pharmacokinetics is defined as what the body does to the
drug. Pharmacokinetics comprehends four main processes: absorption, distribution,
metabolism, and excretion. A relevant pharmacokinetic characterization of a drug is
necessary prior to exposing human subjects to a new chemical entity. In fact,
pharmacokinetic data in two species (rodent and nonrodent) are generally required for
IND application. Generally, this pharmacokinetic data in two species is generated
concurrently with toxicity studies (USFDA, 2010).
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An important question needs to be addressed early in drug development: what
dose is safe and efficacious? Answering this question requires the combined evaluation of
pharmacodynamics and pharmacokinetics. Ideally, PK/PD correlations sampling is done
in the same animal. In occasions, this is not possible due to the nature of PD biomarker,
in this case, a satellite group can be used. These animals must match species, strain,
gender, dose, route of administration, disease state, and sample time to match the study
design as much as possible.
Depending on the disease, animal models can be limited in such a case a
“bridging experiment” in a different strain or species can be carried out to demonstrate
similarity in PK behavior between groups (F. Li et al., 2019; Tuntland et al., 2014). The
gold standard for L. major infection animal model are BALB/c mice. Although infection
with L. major infection has been reported in SD rats, rats did not develop skin ulcerations
(Rostamian & Niknam, 2019).
Pharmacokinetic and pharmacodynamic data in animals can be used to propose a
dosing regimen in humans. The success of this task will be largely dependent on the
selection of an appropriate animal model. For instance, if pharmacokinetic properties are
species-dependent (i.e., in terms of disposition), then extrapolation to humans will be
inaccurate.
Ultimately, the underlying need for studying a drug’s pharmacokinetics is to
establish a relationship between dose and exposure. This relationship is established by
evaluating a concentration time profile, which basically describes the amount of drug in a
biological matrix (i.e., blood, plasma) following drug administration over a period of
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time. From the concentration time profile, several PK parameters can be derived. Table 3
summarizes the most essential PK parameters.
After intravenous administration, the life cycle of a drug in the body starts with its
distribution to different organs and tissues. The drug is eliminated from the body by the
interplay of metabolism and excretion. The disposition of a drug, or how a drug
distributes to tissues and is eliminated from the body, can be determined from an IV
bolus dose. Complete characterization of the pharmacokinetics of a drug entails sampling
the relevant matrix 3-5 half-lives. (Ronald Schoenwal, 2002). Three important pk
parameters characterize disposition at minimum: clearance, volume of distribution and
half-life. Both clearance and volume of distribution are primary pharmacokinetic
parameters, which means they are not derived from other pharmacokinetic parameters.
After oral administration, the drug is absorbed across the intestinal membrane. An
important difference between IV and oral administration is that metabolism can occur
before the drug reaches systemic circulation and site of action.
2.9.2 Pharmacokinetic challenges of new chemical entities
Clearance and volume of distribution have critical implications in half life; thus,
they significantly affect the duration of action. These three parameters, along with rate
and extent of absorption, are key in dose and dose regimen.
Conceptually, clearance refers to the volume cleared of drug per unit time. It is a
function of how efficiently an organ, like the kidney or the liver, excretes or metabolizes
a drug and the blood flow rate to said organ (Gibaldi, 1991). In other words, it describes
how efficiently a drug is eliminated from the body. Clearance establishes a
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Table 3. Fundamental PK Parameters
Parameter

Symbol Description

Dose

D

Administered dose

Cmax

Cmax

Maximum
concentration attained
after drug
administration
Initial concentration

C0

Tmax

Tmax

Volume of
Distribution

Vd

Elimination
rate constant

Kel

Clearance

Cl

Half-life

T1/2

AUC

AUC

Bioavailability F

The time at which Cmax
occurs
The apparent volume in
which a drug
distributes. Relates the
drug concentration to
the amount of drug in
the body
The rate at which a
drug is removed from
the body
The volume of body
fluid cleared per unit
time
The time it takes for the
drug concentration to
decrease by half of its
previous value
A measure of exposure,
area under the curve
The fraction of an
administered dose that
reaches the systemic
circulation

Example Calculation
Units
mg,
Design parameter
mg/Kg
ng/mL
Direct observation

ng/mL

Hr, min

Calculated by back
extrapolation or by
direct measurement
if first time point
occurs at t=0
Direct observation

L

D/(Kel x AUC)

1/hr

Estimated by linear
regression

L/hr

D/AUC

hr

Ln(2)/Kel

Hr x ng/
L
Fraction

Trapezoidal rule
AUCpo/po dose
AUCiv/IV dose
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critical connection between dose and exposure (in terms of AUC), as such any changes in
clearance can have important implications.
Achieving appropriate exposure is imperative for efficacy. Successful NCEs
should achieve and maintain effective drug concentration at the site of action. NCEs with
high clearance values remove drug immediately from the body which translates into short
duration of action. Nonetheless, too stable compounds may also become problematic due
to interactions or even toxicity.
Unsurprisingly, metabolic stability studies assessing a compound’s susceptibility
to metabolism have become standard in the industry. “Softs spots” can be optimized to
decrease metabolic turnover rates (Słoczyńska et al., 2019). For drugs cleared by the
liver, low bioavailability due to high extraction is an important challenge for many oral
drugs. For drugs with clearance approaching blood flow, hepatic extraction ratio
approaches 1 (Benet & Zia-Amirhosseini, 1995), which translates into low
bioavailability.
2.10 Drug metabolism
Drug metabolism constitutes one of the most important components of the
pharmacokinetic properties of an NCE. The importance of metabolism resides on its
effect on activity and toxicity. Understanding the metabolism and excretion of a drug
early in drug development provides valuable information during drug development. This
information is key in identifying potential drug interactions, interindividual difference
and the need for further pharmacological characterization or structure modifications.
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Drugs undergo metabolic biotransformations that generally increase the compound’s
polarity to facilitate excretion. Two important PK parameters are dependent on
metabolism: oral bioavailability and half-life. Consequently, knowledge on the route of
elimination can help drug developers make informed decisions in terms of proper doses
that are both safe and efficacious.
The FDA encourages early in vitro evaluation of drug metabolism and excretion to
prevent unnecessary testing at later stages in drug development. Likewise, FDA urges
scientists to investigate metabolic pathways that account for more than 25% of systemic
clearance (US Food and Drug Administration, 2012).
Drug metabolism is generally classified in phase I and phase II reactions. Phase I
reactions comprehend functionalization reactions either by adding or by unmasking polar
functional groups like hydroxyl, carboxyl or amino in the molecule. On the other hand,
phase II reactions correspond to conjugation reactions in which endogenous compounds
such as glucuronic acid, glutathione, sulfate, or acetyl are covalently linked to functional
groups in the drug (A. Rowland et al., 2013).
In vitro methods for drug metabolism studies are generally carried out on cellular
systems such as hepatocytes or enzyme systems such as microsomal or cytosolic
subcellular fractions. Microsomes express cytochrome P450 (CYP) and UDPglucuronosyltransferase (UGT), which are two major drug metabolizing enzymes
(Knights et al., 2016). Metabolic activity of either enzyme can be evaluated by
monitoring the depletion of parental compounds or the formation of metabolites.
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2.10.1 Phase I metabolism
Phase I metabolism primarily involves oxidation reactions mediated by
cytochrome P450 (CYP). To a lesser extent, flavin monooxidation (FMO), alcohol
dehydrogenase, aldehyde dehydrogenase, and aldehyde oxidase. Nonetheless, other
metabolic reactions such as reduction or hydrolysis of the parent drug by esterases or
amidases may also occur (Sensenhauser, 2014). The cytochrome P450 family is the most
important class of enzymes in drug metabolism.
CYPs are membrane-bound proteins found in the endoplasmic reticulum. CYP
enzymes are found in almost all tissues; however, the liver contains the highest
expression of CYPs (Hrycay & Bandiera, 2008). CYP enzymes metabolize
approximately 90% of the clinically used drugs in the market (Lynch & Neff, 2007);
Thus, their evaluation is critical in drug development.
Cytochrome P450 has a heme bound non-covalently to the enzyme’s active site, which
binds to molecular oxygen via its iron atom. This binding initiates a catalytic cycle in
which protons and electrons are transferred from NADPH and heme-associated
aminoacids side chains to yield, typically, a mono-oxygenated product (Sensenhauser,
2014).
2.10.2 Phase II metabolism
In phase II reactions, phase I metabolites or parent drug undergo conjugation
reactions with hydrophilic moieties such as glucuronic acid, sulfate, or glutathione.
Glucuronidation represents a significant pathway for the drug metabolism of many drugs.
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U-glucuronosyltransferase catalyzes the conjugation of glucuronic acid from
UDP- glucuronic acid (UDPGA) to hydroxyl, carboxyl, or amine groups of drugs. The
elimination of glucuronides comprehends biliary, urinary, and intestinal excretion. UGTs
are divided into two families, UGT1 and UGT2, which are divided into subfamilies
UGT1A, UGT2A and UGT2B.
UGTs are primarily distributed in the liver and intestine. However, they are also
found on the stomach, esophagus, kidney, colon, lung and epithelium. Although UGTs
are primarily located in the ER of cells, they are not exposed to cytosol like CYPs but
rather they predominantly reside in the luminal face of the ER (Caldwell & Yan, 2014).
Glucuronide metabolites are highly hydrophilic and unable to permeate cell
membranes via passive permeation. Thus, the parent compound’s elimination is
dependent on efflux transporters located in various disposition organs. In enterocytes, the
efflux transporters MRP2 and BCRP mediate the efflux of intracellularly formed
glucuronides into the lumen. In the lumen, the glucuronide metabolites can be excreted in
feces or hydrolyzed back into the aglycone. In hepatocytes, MRP2 and BCRP mediate the
efflux of intracellular glucuronides into bile, or they enter systemic circulation via
basolateral efflux transporters such as MRP3. From systemic circulation, organic anion
transporters can uptake glucuronides into the kidney proximal tubular cells to be excreted
via MRP2 or MRP4 (G. Yang et al., 2017).

CHAPTER 3
DESIGN OF THE STUDY
3.1 Central Hypothesis
OJT007 is a MetAP1 inhibitor containing the hydrazine-1-ylidene pharmacophore.
The compound had potent activity against L.major promastigotes and amastigotes, both
in vitro and in vivo (Rodriguez et al., 2020). OJT007 was identified as an excellent
candidate for the oral treatment of cutaneous leishmaniasis based on its promising
efficacy in a mice animal model (Rodriguez et al., 2020). We plan to determine the
feasibility of OJT007 as a drug candidate for clinical application as a new mechanism of
action for the treatment of cutaneous leishmaniasis. We will conduct various types of
preclinical drug development studies including physicochemical characterization,
formulation development, bioanalysis, drug metabolism, and pharmacokinetic
evaluations for OJT007 (Rogge, 2010). We hypothesize that OJT007 is a potential
chemotherapeutic candidate with favorable chemical and biopharmaceutical properties
for the oral treatment of cutaneous leishmaniasis. We propose the following specific
aims.
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3.2 Specific Aims
3.2.1 Aim 1
Develop and validate a bioanalytical assay using LC-MS/MS for the
quantification of OJT007 in rat plasma and urine.
Rationale
To accurately evaluate the absorption, distribution, metabolism, and excretion of
OJT007 in a rat model, we need a sensitive, specific, and reproducible bioanalytical assay
to quantitate OJT007 concentrations in plasma and urine. Unlike conventional HPLC
with UV detection systems, which were limited by sensitivity and significant interference
from biological media, LC-MS/MS offers high sensitivity, excellent specificity, and good
reproducibility. Furthermore, LC-MS/MS requires very small quantity of biological
samples (i.e., 10 uL – 20 uL plasma) for quantification. In this aim we develop a
bioanalytical assay suitable for characterization of pharmacokinetics of OJT007 in rats
after oral and intravenous administration.
3.2.2 Aim 2
Investigate the physicochemical properties of OJT007 and develop a suitable
formulation for preclinical studies in animals.
Rationale
A suitable formulation of OJT007 is a prerequisite for successful in vivo studies.
This task entails a thorough understanding of the physicochemical characteristics of the
drug in order to design of a suitable formulation. All formulation efforts are especially
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important and challenging for drugs with poor solubility. Furthermore, formulation must
be designed with suitable excipients. In this aim we develop a cosolvent formulation for
intravenous and oral administration of OJT007.
3.2.3 Aim 3
Investigate the in vitro hepatic metabolism of OJT007 in human microsomes and
rat liver and intestine microsomes.
Rationale
Drug metabolism is an integral part of drug development. Understanding how and
via what pathways a drug candidate is/are metabolized would help not only to know the
behavior of the drug in vivo but also to design optimal dosage regimen. In vitro
metabolism studies using liver microsomes is an authentic way of estimating intrinsic
hepatic clearance of a compound and identifying potential metabolites. It also provides
mechanistic information about pre-systemic metabolism in relation to oral bioavailability
of the drug. In this aim we explore metabolic processes of OJT007.
3.2.4 Aim 4
Determine pharmacokinetic profiles of OJT007 following intravenous and oral
administration using rat as an animal model
Rationale
Poor pharmacokinetic properties accounts for 40% of attrition in phase I clinical
trials (Ajavon & Taft, 2010). An understanding of preclinical drug disposition in animal
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models aids in the knowledge base for a drug candidate to determine whether it is
feasible to move into clinical evaluations or recommend for early elimination.
We will characterize the disposition and elimination profiles of OJT007 following
intravenous administration. Oral bioavailability of OJT007 will be assessed accordingly.
Furthermore, the impact of stomach acid degradation on OJT007 bioavailability will also
be evaluated.
3.3 Materials
3.3.1 Chemicals and Drugs
•

Acepromazine (10 mg/mL) injection, purchased from Hospira (Lake Forest, IL),
was used as part of the anesthetic cocktail for jugular vein cannulation surgery.

•

Alamethicin purchased from Sigma-Aldrich (St. Louis, MO), was used for
preparation of solution B for the UGT regenerating system.

•

Bupivacaine HCl injection USP (0.5%, 5mg/mL), purchased from Hospira (Lake
Forest, IL), was used to provide post-surgery analgesia to the animals.

•

Deionized water, produced in the lab with a Barnstead TM Smart2Pure TM water
purification system (Thermo Fisher Scientific, Waltham, MA), was used in
OJT007 formulation.

•

Dimethyl sulfoxide (DMSO), purchased from Sigma-Aldrich (St. Louis, MO),
was used for studying solubility of OJT007.

45

•

β- Glucuronidase, from Escherichia coli- Type IX-A, lyophilized powder,
1434438 units / g protein purchased from Sigma-Aldrich (St. Louis, MO), was
used for glucuronide hydrolysis

•

Formic Acid, purchased from Sigma-Aldrich (St. Louis, MO), was used to
enhance the ionization of OJT007 in the LC-MS/MS method development.

•

Heparin sodium injection (1000 units/mL), purchased from Hospira (Lake Forest,
IL), was used as anticoagulant in animal experiments.

•

Human liver microsomes, 20-Donor Pool, Mixed Gender purchased from Corning
Gentest (Corning, NY), were used for in vitro incubations.

•

Ketamine injection (100 mg/mL), purchased from Hospira (Lake Forest, IL), was
used as part of the anesthetic cocktail for jugular vein cannulation surgery.

•

LC-MS grade acetonitrile, purchased from J.T. Baker Chemical Co. (Phillipsburg,
NJ), was used to prepare mobile phase for the quantification of OJT007 by LCMS/MS.

•

LC-MS grade water, purchased J.T. Baker Chemical Co. (Phillipsburg, NJ), was
used to prepare mobile phase for the quantification of OJT007 by LC-MS/MS.

•

LC-MS grade methanol, procured from Mallinckrodt Baker (Phillipsburg, NJ,
USA), was used for solubility studies of OJT007.

•

Monopotassium phosphate (KH2PO4), Dipotassium phosphate (K2HPO4) and KPI
buffer was made using KH2PO4 and K2HPO4 and the pH was adjusted to 7.4 using
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sodium hydroxide and hydrochloride. All of which were purchased from VWR
(Radnor, PA).
•

Magnesium Chloride purchased from Sigma (St. Louis, MO), was used for
Solution A UGT regenerating system preparation

•

OJT007 (purity ≥ 98%) was purchased from MolPort (Riga, Latvia).

•

Polyethylene glycol (PEG 400), purchased from Wood Scientific (Houston, TX),
was used to prepare OJT007 formulations.

•

Polysorbate 80 (Tween 80®), purchased from Sigma-Aldrich (St. Louis, MO),
was used for the solubility test of OJT007.

•

Rabeprazole sodium, purchased from Sigma-Aldrich (St. Louis, MO), was used to
control gastric acid secretion in rats.

•

Rat (Sprague-Dawley) pooled liver microsomes, male, purchased from Corning
Gentest (Corning, NY), were used for in vitro incubations.

•

Rat (Sprague-Dawley) pooled intestinal microsomes, male, were prepared inhouse according to previously published methods for in vitro incubations.

•

Saccharolactone purchases from Sigma-Aldrich (St. Louis, MO), was used for
preparation of solution B for the UGT regenerating system.

•

Sodium chloride solution, 0.85 %, (normal saline) purchased from Sigma-Aldrich
(St. Louis, MO), was used to dilute dosing solutions for animal dosing.
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•

Solution A, purchased from Corning Gentest (Corning, NY), was used for
NADPH regenerating system for microsomal incubations.

•

Solution B, purchased from Corning Gentest (Corning, NY), was used for
NADPH regenerating system for microsomal incubations.

•

Uridine 5’-diphosphoglucuronic acid trisodium salt purchased from Sigma (St.
Louis, MO), was used for solution B UGT regenerating system for microsomal
incubations.

•

Voriconazole, purchased from Sigma-Aldrich (St. Louis, MO), was used as
internal standard for LC-MS/MS method.

•

Xylazine injection (100 mg/mL), purchased from Hospira (Lake Forest, IL), was
used as part of the anesthetic cocktail for jugular vein cannulation surgery.

3.3.2 Supplies
•

1 cc sterile tuberculin slip tip syringes and PrecisionGlide® 23 G TW needles,
purchased from Becton Dickinson & Co. (Franklin Lakes, NJ), were used during
animal experiments for intra-venous dosing and blood sampling.

•

Amber scintillation vials (20 mL), purchased from VWR (West Chester, PA),
were used as storage containers.

•

Amicon Ultra – 0.5 mL Centrifugal Filters, MWCO 3k, purchased from EMD
Millipore (Billerica, MA), were used to determine the plasma protein binding of
OJT007.
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•

Auto-sampler propylene injection vials (Clear; 100 µL), purchased from
ChromTech (Apple Valley, MN), were used to hold samples for injection in the
LC-MS/MS assays.

•

Cotton tipped applicators (6”), purchased from Baxter Healthcare Co (McGaw
Park, IL), were used during animal surgeries to stop bleeding and apply topical
contents during surgery.

•

Face masks, purchased from AlphaProTech, Inc. (Salt Lake City, UT), were worn
while using chemicals and handling animals.

•

Gauze (3 in x 3 in), purchased from Tyco Healthcare (Mansfield, MA), were used
to suppress bleeding and clean-up incision sites during animal surgeries.

•

Insulin syringe (1 mL, sterilized), purchased from Becton Dickinson & Co.
(Franklin Lakes, NJ), were used for administration of anesthesia agents during
animal experiments.

•

Membrane filters (47 mm, 0.45 μm, hydrophilic polypropylene, Pall Corp., Ann
Arbor, MI) were used to filter mobile phase for LC-MS/MS analysis.

•

Microcentrifuge tubes (amber, clear and assorted colors, 1.5 mL), purchased from
VWR (West Chester, PA), were used in sample preparation for microsomal
incubations and LC-MS/MS analysis.

•

Nylon 2/0 and 3/0 surgical sutures, purchased from Henry Schein Inc. (Melville,
NY), were used during animal surgery to close incisions and secure the jugular
vein cannula.
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•

Pipette tips (10 μL, 20 μL, 250 μL, and 1000 μL), purchased from Rainin
Instrument (Oakland, CA), were used along with the appropriate mechanical
pipettes for volumetric transfer of liquids.

•

Polyethylene tube (I.D. 0.023”, O.D. 0.038”), purchased from Becton Dickson
Intramedic & Co. (Franklin Lakes, NJ), were used for blood sampling via jugular
vein cannula

•

Powder-free latex examination gloves, purchased from VWR (West Chester, PA),
were worn during all laboratory and animal experiments.

•

Standard silicone tubing (I.D. 0.025”, O.D. 0.047”), purchased from HelixMark
(Carpinteria, CA), were used as the soft front of the polyethylene tubing.

•

Syringe filters (0.45 μm, HPLC certified), purchased from VWR (Radnor, PA),
were used to sterilize anesthesia cocktail.

•

Syringes (1 ml, sterilized, single use), purchased from Becton Dickson &Co.
(Sparks, MD), were used for blood sampling.

3.3.3 Equipment, Apparatus and Software
•

Analyst® software v1.6.2, purchased from SCIEX (Foster City, CA), was used to
control and acquire data from the LC-MS/MS system.

•

Electronic Weighing Balances (AB204-S and AT261 Delta Range), purchased
from Mettler Toledo (Columbus, OH), were used to weigh all solid-state
excipients and drugs.
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•

Empower 3® software (Milford, MA) was used to control and acquire data from
the UPLC system.

•

Eppendorf Centrifuge 5427 R (Enfield, CT) was used to centrifuge samples and
working solutions to enable collection of supernatants.

•

Gastight glass syringe, purchased from Hamilton Company (Reno, NV), was used
to tune the mass spectrometer parameters for OJT007 and IS.

•

Sigma Plot v11.0, purchased from Graph Pad Software Inc. (La Jolla, CA), was
used to generate plots and for statistical analysis of data.

•

LC-MS/MS system consisting of the following was used for the quantification of
OJT007
o 4000 QTRAP MS/MS system purchased from SCIEX (Foster City, CA)
o Genius ABN2ZA Tri Gas Generator purchased from Peak Scientific
(Billerica, MA)
o

Shimadzu Nexera X2 UHPLC System (Columbia, MD)

o Acquity UPLC® BEH C18 UHPLC column (1.7µm, 2.1 x 50 mm)
purchased from Waters (Milford, MA)
•

Phoenix WinNolin® 8.3, purchased from Certara (St. Louis, MO), was used to
estimate pharmacokinetic parameters from rat data.

•

Pipettes, purchased from Rainin Instrument (Oakland, CA) and Eppendorf
(Hamburg, Germany), were used for volumetric measurements.
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•

Precision™ Shaking Water Baths, Thermo Scientific™ (Waltham, MA) was used
to incubate samples during in-vitro metabolism studies.

•

Syringe Pump 11 PLUS, purchased from Harvard Apparatus (Holliston, MA),
was used to tune the mass spectrometer parameters for OJT007 and IS.

•

Vortex machines (Vortex-Genie® 2), purchased from Scientific Industries
(Bohemia, NY), were used mix sample preparations.

•

Waters Acquity UPLC with photodiode array detector (Milford, MA)

3.3.4 Animals
The animal protocol used in this work was reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) at Texas Southern University.
Additionally, all animal studies were conducted in compliance with the National Institute
of Health “Guide for the Care and Use of Laboratory Animals, 8th Edition”. Experiments
were carried out using adult male Sprague-Dawley rats (mean body weight 350g)
purchased from Envigo RMS, LLC, Alice, TX. Upon arrival, the animals were housed
under normal conditions which includes free access to food and water, a room
temperature environment with 12-hour light-dark cycles from 6 am to 6 pm daily.
These conditions were maintained for one week before starting animal
experiments to allow for adequate acclimatization of the animal. The animals were
implanted with a cannula tube in the left jugular under anesthesia and allowed to recover
for 24 hours before initiating dosing.

52

3.4 Methods
3.4.1 LC-MS/MS Assay Development
A LC-MS/MS analytical method was developed to quantitate OJT007
concentrations in plasma and urine samples collected from pharmacokinetic studies of
OJT007 in rats. The method development required optimization of the massspectrometric conditions to achieve the best signal to noise ratio and optimization of the
chromatographic conditions to ensure the best selectivity and minimize matrix effect due
to interference in the biological matrix.
3.4.1.1 Chromatography
The LC analysis was accomplished using a Shimadzu Nexera X2 UHPLC system
(Columbia, MD, USA). The chromatographic separation was achieved using an Acquity
UPLC BEH C18 column (50 × 2.1 mm, 1.7 μm) with a gradient mobile phase at flow rate
of 0.4 mL/min. The sample injection volume was 2 μL, and the mobile phase consisted of
0.1% v/v formic acid in water (A) and 0.1% v/v formic acid in acetonitrile (B). Gradient
elution was employed with 5% to 98% B from time 0 to 1.8 min and was kept constant at
98% B for 1.7 min, then 98% B was changed to 5% B from 3.5 to 3.7 min and kept
constant at 5% from 3.7 min to 5 min (Table 4).
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Table 4: Summary of Gradient Elution Profile Applied to the Chromatographic
Separation of OJT007 and IS

Time
(min)

Flow Rate
(mL/min)
0.4

Mobile
Phase A
(%)
95

Mobile
Phase B
(%)
5

0
1.80

0.4

2

98

3.50

0.4

2

98

3.70

0.4

95

5

5.0

0.4

95

5
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Figure 6: Gradient elution plot depicting changing concentration of solvent B (0.1%
formic acid in Acetonitrile)
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3.4.1.2 MS/MS Detection
The MS/MS analysis was performed on a 4000 QTRAP® triple quadrupole mass
spectrometer system equipped with a Turbo Ion Spray ion source (Sciex, Redwood City,
CA). The hybrid triple quadrupole LIT (linear ion trap) mass spectrometer is equipped
with a Turbo V™ ion source. Pure nitrogen used as curtain gas, and source and exhaust
gases were generated by a Peak Scientific (GENIUS ABN2ZA) Tri Gas Generator.
Voriconazole was used as internal standard (IS). The quantification was performed using
multiple-ion reaction monitoring (MRM) in positive mode, with the transitions of m/z
325 → m/z 205 for OJT007 (Fig. 2) and m/z 350 → m/z 101 for IS. The source
parameters were set as follows: ion spray voltage, 4500 V; ion source temperature,
500°C; nebulizer gas, 50 psi; heater gas, 40 psi; curtain gas, 25 psi; and the collision gas,
high. The compound-dependent parameters for OJT007 and IS were optimized with
entrance potential (EP), 10 V and 10 V; declustering potential (DP), 105 V and 56 V;
collision energy (CE), 30 V and 105 V; and collision cell exit potential (CXP), 11 V and
8 V, respectively. Analyst® Software 1.6.2 (Redwood City, CA, USA) was used to
control the LC-MS/MS system and analyze the data. The compound dependent electronic
parameters for the MS/MS acquisition of OJT007 and IS are summarized in Table 5.

Figure 7: Product ion spectra of OJT007
56
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Table 5: Electronic Parameters for MS/MS Acquisition of OJT007 and IS
Parent

Transition
(m/z)

DP (V)

CE (V)

EP (V)

CXP (V)

325→205

Dwell
Time
(msec)
150

OJT00
7
IS

105

30

10

11

350→101

150

56

105

10

8
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3.4.1.3 Standard and Quality Control Samples
The stock solution of OJT007 was prepared by dissolving the solid compound in
5% DMSO and 95% methanol at a concentration of 1 mg/mL and was stored at −80 °C
until it was used. The IS was prepared by dissolving voriconazole in acetonitrile at the
concentration of 1 mg/mL. The OJT007 working solutions were prepared by diluting the
stock solution in 50% acetonitrile in water at final concentrations of 10, 5, 2.5, 1, 0.5, 0.25,
0.10, and 0.05 μg/mL. The OJT007 quality control (QC) working solutions were prepared
by diluting the stock solution in 50% acetonitrile in water at final concentrations of 0.15,
0.75 and 7.5 μg/mL. The IS working solution was prepared by diluting the 1 mg/mL stock
solution with 100% acetonitrile to obtain a concentration of 300 ng/mL. Plasma and urine
samples were processed by protein precipitation. A series of standard samples were
prepared by spiking the working solutions (5 μL) into blank rat plasma or urine (45 μL) to
obtain the following concentrations of OJT007: 5, 10, 25, 50, 100, 250, 500, and 1000
ng/mL. The QC samples were prepared by spiking QC working solutions into blank rat
plasma or urine to obtain concentrations of 15 ng/mL (low), 75 ng/mL (medium) and 750
ng/mL (high), respectively. The mixture was vortexed for 30 seconds and then centrifuged
at 14,000 rpm for 15 minutes. The resulting supernatant was then transferred to an autosampler vial for LC−MS/MS analysis.
3.4.1.4 Plasma and Urine Sample Preparation
Plasma samples stored at −80 °C were thawed at room temperature. An aliquot (50
μL) of plasma was extracted for OJT007 using protein precipitation by adding 250 μL of
acetonitrile containing the internal standard (300 ng/mL). The mixture was vortexed for 30
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seconds and centrifuged at 14,000 rpm for 15 min at 4°C. An aliquot of the supernatant
was injected into the LC-MS/MS for quantitative analysis.
3.4.2 LC-MS/MS Method Validation
The LC-MS/MS assay was validated according to Center for Drug Evaluation and
Research (CDER) “Guidance for Industry: Bioanalytical Method Validation” with respect
to specificity, lower limit of quantification (LLOQ), linearity and range, accuracy and
precision, extraction recovery, matrix effect, carryover effect, stability and dilution
integrity (USFDA, 2018).
3.4.2.1 Linearity and Sensitivity
Linear calibration curves in rat plasma and urine were generated by plotting the
peak area ratio of OJT007 to IS against known standard concentrations of OJT007. The
slope, intercept, and coefficient of determination were estimated using least squares linear
regression method. The lower limit of quantification (LLOQ) was evaluated based on the
signal to noise ratio of at least 5.
3.4.2.2 Calibration Curve
Calibration curves in blank rat plasma or urine were obtained by plotting the peak
area ratio of OJT007 to IS versus the known concentration of OJT007. Least-squares linear
regression method with 1/x2 weighting was applied to obtain the slope, intercept, and
correlation coefficient. The lower limit of quantification (LLOQ) was evaluated based on
the signal-to-noise ratio of at least 5. The LLOQ is the minimal quantifiable concentration
point in the calibration curve at which precision (coefficient of variation, CV) should be
within 20%, and accuracy (relative error, RE) should be within 20% of nominal value.
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3.4.2.3 Stability in Plasma and Urine
All stability studies were evaluated in blank rat plasma or urine at low, medium,
and high QC levels (15, 75, and 750 ng/mL, respectively) using triplicates at each
concentration level. All the samples were compared to freshly prepared samples at the same
concentrations. Short-term QC samples in blank rat plasma or urine were freshly prepared
and left on the benchtop at room temperature for 4 hours (short-term benchtop). Freezethaw (FT) stability samples were exposed to three cycles of freeze (-80°C) and thaw (RT,
room temperature). The auto-sampler stability of processed samples was determined by
comparing processed plasma or urine that remained in the auto-sampler for 24 hours at
15°C. Long-term storage stability samples were freshly prepared and stored at -80°C for
14 days.
3.4.2.4 Extraction Recovery and Matrix Effect
To examine the extraction recovery and matrix effect, QC samples were evaluated
at three concentration levels (15, 75 and 750 ng/mL, n=6, respectively). The extraction
recovery and matrix effect were calculated according to Equation 3 and Equation 4.
!

Extraction Recovery % =

"100%

(3)

!

Where Responsepre-extraction spike is the average area count for OJT007 that has undergone the
extraction process; and Responsepost-extraction

spike

is for OJT007 samples spiked into

extracted matrix after the extraction procedure. The matrix factor of OJT007 was calculated
according to:
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Matrix Factor %= (
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!

) x100%

!

(4)
Where Responsepost-extraction spike is the average area count for OJT007 spiked into matrix
after the extraction procedure, and Responsematrix-free

spike

is the average area count for

OJT007 samples at the same concentration of OJT007 in neat solution (50% acetonitrile in
water).
3.4.2.5 Accuracy and Precision
To evaluate the intra-day or inter-day assay accuracy and precision, the LLOQ and
QC samples were analyzed on the same day or three subsequent days. Experiments were
conducted in replicates of N=6 for each testing level. The assay accuracy and precision
were expressed in relative error from the theoretical drug concentration (RE%) and
coefficient of variation (CV%), respectively.
3.4.2.6 Dilution Integrity
The dilution integrity was assessed by determining the accuracy and precision of
the measurement of rat plasma spiked with OJT007 5X upper limit of quantification
(ULOQ). The effect of 1:5, 1:10, 1:20 and 1:50 dilution with blank rat plasma was
measured. Following LC-MS/MS analysis, the quantitated concentrations were corrected
with their respective dilution factor, and accuracy and precision were determined. This
experiment was conducted in sextuplets.
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3.4.3 UPLC Quantification Method Development
Nonvolatile buffers (i.e., phosphates) and salts have the tendency to remain
deposited on the ion source, which contaminates the electrodes in the ion source in turn
resulting in a reduction in signal intensity (Mannur et al., 2011). Furthermore, PEG,
surfactants and PEG-like solvents have the tendency to decrease signal by interfering with
ionization (Keller et al., 2008). To prevent ion source contamination in the buffered in vitro
metabolism experiments and during solubility studies, a UPLC analytical method was
developed to quantitate OJT007 and metabolites concentrations. The UPLC system
consisted of Waters Acquity UPLC with photodiode array detector and Empower software;
column, BEH C18, (1.7μm, 2.1 × 50 mm. The mobile phase consisted of 100% acetonitrile
(B) and 0.1% formic acid in water (A). Gradient elution was employed with 5% to 98% B
from time 0 to 2.8 min and was kept constant at 98% B for 1.2 min, then 98% B was
changed to 5% B from 4 to 5.2 min, and kept constant at 5% from 5.2 min to 6 min. UV
detection wavelength was 343 nm, and 10 μL injection volume. The Standard curve
samples containing OJT007 were prepared in solution or phosphate buffer and injected into
UPLC for quantification.
3.4.4 Preformulation Studies
3.4.4.1 Solubility in Common Solvents
The solubility of OJT007 in common pharmaceutical excipients were determined
using the shake-flask method. Briefly, excess amounts of OJT007 were added into 1 mL
of solvent and placed on a mechanical shaker at room temperature for 24 hours. Each
sample was centrifuged at 14000 rpm at 4oC for 15 minutes. The supernatant was collected
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and filtered using sterile 0.22 μm syringe filters before UPLC injection. The following
solvents were evaluated: DMSO, polysorbate 80, ethanol, labrasol, PEG 400 and deionized
(DI) water.
3.4.4.2 pH Solubility Profiles
The solubility of OJT007 was determined under pH conditions ranging from 3-7.
Standard USP buffers were prepared and used for this experiment: 0.2 M Hydrochloric
acid for pH 1.2, 0.2 M acid phthalate buffer for pH 3-4, neutralized phthalate buffer for pH
5, and 0.2 M phosphate buffer for pH 6-7. Excess OJT007 was added to buffered systems.
The mixtures were placed in a water bath at room temperature for 24 hours shaking at 50
rpm to reach solubilization equilibration. The samples were centrifuged and filtered using
sterile 0.22 μm syringe filters. The filtrates were injected onto the UPLC system for
quantification of OJT007 concentrations, and subsequently calculating solubility of
OJT007 in various pH conditions. Each buffered cosolvent was tested in triplicate.
3.4.4.3 Solution State pH Stability
The effect of varying pH conditions on the stability of the drug was evaluated by
incubating OJT007 in buffers of various pH. Standard USP buffers (USP-NF) were
prepared and used for this experiment: 0.2 M Hydrochloric acid for pH 1.2 and 2, 0.2 M
acid phthalate buffer for pH 3-4, neutralized phthalate buffer for pH 5, 0.2 M phosphate
buffer for pH 6-8 and 0.2 M borate buffer for pH 9-10. Buffers spiked with OJT007 (100
μg/mL) were incubated at 37oC. Aliquots of the buffer solution were collected at 0, 0.25,
0.5, 0.75, 1, 2, 3, 4, 5, 7 and 24 hrs. The collected samples were diluted with 50%
acetonitrile in water to obtain appropriate concentrations and analyzed by the UPLC.
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3.4.4.4 UV-metric pKa measurements
The experimental pKa was determined by UV-metric method with a Sirius T3
automated titrator instrument (Pion, Woburn, MA). This method measures the UV
absorbance changes of chromophores of the substance as a function of pH. The Sirius T3
machine is equipped with an Ag/AgCl double junction electrode to measure the pH, a dip
probe attached to the UV spectrophotometer, a stirrer, and titration capabilities. The stock
solution for OJT007 were prepared by dissolving the drug in DMSO. During the
experiment 5 uL of stock solution were delivered to the Sirius T3 glass vial to achieve a
final concentration of 20 mM (to ensure appropriate absorbance without saturating the
detector). The titration experiments were conducted at 25oC in 0.15 M KCl solution
under argon flow to prevent CO2 absorption that could potentially affect pH. The pH was
titrated between 1.8 and 12.2 via de addition of 0.5 M HCl and 0.5 M KOH starting from
low to high pH (so titration would start when the compound was more soluble). The UV
absorbance data was collected from 160-760 nm; However, the region of 250-450 nm
was used for pKa determination.
3.4.4.5 Cosolvent Formulation
Water-miscible solvents in which OJT007 has good solubility were used to
develop a cosolvent formulation to improve the poor aqueous solubility of the drug.
Several solvents with varying ratios and compositions were tested to make the cosolvent
formulation of OJT007. Varying concentration of OJT007, ranging from 1-10 mg/mL
were incorporated in the cosolvent system. The optimal formulation to be used in the
preclinical studies was selected on the basis of precipitation upon dilution with normal
saline and formulation stability.
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3.4.5 Plasma Protein Binding
Plasma protein binding (PPB) was evaluated using a modified ultra-filtration
technique (Bowers et al., 1984; Robinson et al., 2015; Toma et al., 2021). Three different
concentrations (50, 75 and 100 μg/mL) of OJT007, were selected to ensure that unbound
fraction could be accurately quantitated with the developed method. Briefly, stock
solutions of three different concentrations (50, 75 and 100 μg/mL) prepared in 50%
acetonitrile were spiked into blank rat plasma. The plasma was incubated at 37°C for 30
min. The mixture was transferred into Amicon Ultra-0.5 mL centrifugal filters of 30kD
(EMD Millipore Corporation, Billerica, MA) for ultrafiltration at 14,000 rpm for 15 min
at 4°C. Filtrate and non-filtrate samples were spiked with internal standard and analyzed
using the LC-MS/MS. Percent PPB was calculated according to Equation 5.
Plasma protein binding% = ( )

)*
* +),

) x 100%

(5)

Where Cb and Cu are bound and unbound OJT007 concentrations measured in the unfiltrated sample and filtrated, respectively. Experiments were conducted in triplicate.
3.4.6 Metabolism of OJT007 in Hepatic Cytochrome P450 Phase I and II Reaction
Systems
To determine whether OJT007 is metabolized by cytochrome P450 (CYP) or
uridine glucuronosyltransferase enzymes (UGT), rat and human liver microsomes and
intestine microsomes were used.
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3.4.6.1 In Vitro Metabolic Studies - CYP Reaction System
The NADPH regenerating system consists of solution A and solution B which
after mixing, generate the NADPH needed for oxidation reactions. Solution A contains
26 mM NADP+, 66 mM glucose-6-phosphate, and 66 mM magnesium chloride in water
while and solution B contains 40 U/mL glucose-6-phosphate dehydrogenase in 5 mM
sodium citrate for generating NADPH. The in vitro cytochrome P450 phase I oxidation
metabolism of OJT007 was evaluated according to previously described incubation
procedures (Yang et al, 2010). Briefly, rat liver microsomes (final concentration 10 mg
protein/mL), 50 mM phosphate buffer at pH 7.4 (KPI), test compound (50 μM), 30 μL
NADPH regenerating solution A and 6 μL NADPH regenerating solution B were
incubated for 28 hours at 37°C (600 μL total assay volume). Aliquots of 100 μL were
taken at different time points and quenched with 50 μL of ice-cold acetonitrile containing
0.6% formic acid. The samples were vortexed for 30 seconds, centrifuged at 14,000 rpm
and the supernatant was injected into UPLC system for analysis. A negative control was
prepared without addition of NADPH.
3.4.6.2 In Vitro Metabolic Studies - UGT Reaction System
The in vitro uridine glucuronosyltransferase (UGT) phase II glucuronidation of
OJT007 was evaluated according to previously described incubation procedures
(Jiamboonsri et al., 2016) . Rat liver microsomes (final concentration of 0.035 mg
protein/mL or 0.5 mg protein/mL), rat intestine microsomes (final concentration of 0.5
mg protein/mL) or human liver microsomes (final concentration of 0.5 mg protein/mL)
were mixed with 0.88 mM magnesium chloride, 4.4 mM saccharolactone, 0.022 mg/mL
alamethicin, 15 μM, test compound and 3.5 mM UDPGA, which was added last. The
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mixture (final volume=200 μL) was incubated at 37°C for 1 hr or 2 hr. The reaction was
stopped by addition of 50 μL acetonitrile containing 0.6% formic acid. The samples were
vortexed for 30 seconds, centrifuge at 14,000 rpm and the supernatant was injected into
UPLC system for analysis of OJT007 and metabolites. Genistein (15 μM) was used as a
reference substrate for UGT. A negative control was prepared without addition of
cofactor.
3.4.7 Determination of Molar Extinction Coefficient of OJT007 Glucuronide
Because of the lack of OJT007 glucuronide authentic standards, the OJT007
standard curve was used for quantification of OJT007 glucuronide using a conversion
factor (K). Determination of conversion factors has been described previously (Gao et al.,
2011; Z. Yang, Zhu, et al., 2010). Briefly, an OJT007 standard curve was prepared in KPI
without microsomes. The conversion factors were determined by comparing the UV
absorption peak area of OJT007 and those of the glucuronide at absorption wavelength of
343 nm with following its 100% conversion to after a complete glucuronide. The
difference in peak area of glucuronide metabolite (PAc) and peak area of OJT007 (PAo)
was calculated to be the ratio K. The average conversion factor (K) at three different
concentrations (2.5, 10 and 50 µM) was used for estimating metabolite concentration.
-.

K = -.

The calculated conversion factor can be used to calculate the metabolite
concentration using peak area of metabolite and the slope of the calibration curve
obtained from parent compound (a1).

(6)

68
-./

C=0123

(7)

3.4.8 Metabolite Identification
3.4.8.1 Hydrolysis by β-glucuronidases
β-glucuronidases are enzymes which catalyze the hydrolysis of O- or Sglycosidic moieties allowing for the liberation of aglycones from glycosides (Sui et al.,
2021). Following OJT007 biosynthesis of the glucuronide metabolite using liver
microsomes for 2 hours, the incubates were centrifuged at 14,000 rpm for 15 min. The
supernatant (200μL) was added to 50μL of the β-glucuronidase solution, which was
prepared in KPI pH 7.4 at a concentration of 4,000 units/mL. Then, the mixtures were
incubated at 37°C for 2 hr to hydrolyze the glucuronide into parent compound. Aliquots
of the mixture were collected at 0, 1 and 2 hours and added into the ice-cold 0.6%formic
acid in acetonitrile solution to stop the reaction. The mixtures were then vortexed for 30
seconds and centrifuged at 14,000 rpm for 15 min. The supernatant of this mixture was
analyzed for OJT007 and glucuronide concentrations by a UPLC method. The control
reaction consisted of an equivalent volume of KPI instead of the enzyme solution. The
remaining glucuronide metabolite after hydrolysis was expressed as residual percent: the
peak area of the analyte at different time points relative to the peak area of the same
analyte at time zero multiplied by 100. The produced aglycone or unconjugated molecule
was expressed as the concentration of the analyte at each time point.
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3.4.8.2 Identification of Metabolites
After biosynthesis of the glucuronide, the metabolite solution was analyzed by
LC-MS/MS to identify the glucuronide. UPLC analysis was accomplished using a
Shimadzu Nexera X2 UHPLC system (Columbia, MD, USA) coupled with a 4000
QTRAP® triple quadrupole mass spectrometer system equipped with a Turbo Ion Spray
ion source (AB Sciex. Redwood City, CA, USA) using the instrument conditions
optimized on section 3.4.1.2. The mass spectrometer used Q1MI, product ion (MS2),
Neutral Loss (NL) and Precursor ion (PI) scan to identify the metabolites.
3.4.9 Metabolic Stability Data Analysis
The half life was calculated based on a single time point assay as done by others (Di et
al., 2004). Briefly, half-life was calculated based on first-order reaction kinetics using
Equation 8, which allows to calculate the percentage of the parent remaining at certain
incubation time. For screening purposes, 60 minutes was selected as optimal time for
incubation as it would give a higher predictive limit and would allow to differentiate
OJT007 microsomal stability.
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3.4.10 Glucuronidation Metabolic Kinetics
The kinetic parameters of OJT007 glucuronidation were determined by measuring
the initial glucuronidation rates of OJT007 at 1 hour after incubation with liver
microsomes according to the glucuronidation assay described in section 3.6.2. OJT007
concentrations evaluated ranged from 1.25−100 μM at a 0.035 mg of protein/mL. The
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glucuronidation rates were calculated as the amount of formed glucuronide per reaction
time per protein amount (nmol/min/mg). Kinetic data were analyzed according to the
Eadie-Hofstee plot for selection of the appropriate equation (Seibert & Tracy, 2014). If
the Eadie-Hofstee plot was linear, the formation rate at different substrate concentration
were fit to the standard Michaelis-Menten equation:
L=

M'

1)

(9)

0' +)

Where Km is the Michaelis-Menten constant, and Vmax is the maximum rate of
glucuronidation. GraphPad Prism software (version 7.3 for Windows; GraphPad
Software, La Jolla, CA) was used. Visual inspection of fitted functions was used to select
the best-fit enzyme kinetic model.
3.4.11 Prediction of In Vivo Clearance From In Vitro Hepatic Data
The in vitro intrinsic clearance was scaled-up to predict the in vivo intrinsic
clearance. For microsomes a standard value of 45 mg of protein/g of liver weight is used.
The intrinsic clearance values were based on total concentrations not on free
concentrations (Brian Houston, 1994; Obach, n.d.). Likewise, a value of 40 g of liver/Kg
of body weight was applied in the calculation. (Davies & Morris, 1993)
N6D

GMHO
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Conversion of the intrinsic clearance to clearance in rats was done using the wellstirred model of hepatic clearance. It has been reported that for highly protein bound
lipophilic amines or neutral molecules, inclusion of PPB data yielded severe Cl
underpredictions. It appears that for compounds highly bound to microsomes, the
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intrinsic clearance is underestimated. In this case, inclusion of the free fraction term
leads to an underprediction of clearance (Obach, 1999; Obach et al., 1997). Due to this
we will use the well stirred model as follow:
)R

1W

)R

+W

ClH=

(11)

3.4.12 Pharmacokinetic Studies
3.4.12.1 General animal procedures
Jugular vein cannulation was performed under anesthesia using an aqueous
anesthetic cocktail composed of ketamine: acetopromazine: xylazine (50:3.3:3.3 mg/Kg)
at a dose of 1 mL/Kg the day before the study. A cannula, composed of silicone elastic
tubing (0.02” I.D. and 0.037” O.D.) was inserted into the right jugular vein, secured with
a silk suture tunneled subcutaneously and exteriorized in the dorsal infrascapular area.
The surgical incision was closed with surgical sutures. Cannula patency was maintained
by flushing the cannula line daily with 0.5 mL of sterile heparinized saline solution (100
units/mL).
3.4.12.2 Evaluation of Oral Bioavailability
Cross-over design was used in this study to evaluate the oral bioavailability of
OJT007. Adult male SD rats (n=5) weighing 300 – 350 g were cannulated through the
jugular vein under anesthesia one day before the study. Each rat received a 5 mg/kg
intravenous dose of OJT007 cosolvent formulation. Serial blood samples (100-150 µL
each) were collected from each rat before dose and at 2, 5, 15, 30, 60, 90 minutes, and 2,
4, 6, 8, 10, and 24 hours post dose. After blood centrifugation at 13000 rpm for 3
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minutes, the plasma supernatants were collected, and immediately stored in -800C and
analyzed within 14 days. We also collected urine samples up to 24 hours post dose and
immediately stored in -800C and analyzed within 14 days. Following a week washout
period, the rats were fasted overnight and for four hours after receiving a 10 mg/kg oral
dose of OJT007 cosolvent formulation. Water was always available to the rats. Again,
serial blood samples were collected before dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8,
10, 24 hours post dose. Blood samples were centrifuged at 13000 rpm for 3 minutes, and
the supernatants were collected. Urine samples were collected up to 24 hours after dose.
Urine and plasma samples were stored at -800C and analyzed by LC-MS/MS analysis
within 14 days.
3.4.12.3 Drug Interaction Studies following Co-administration of OJT007 and
Rabeprazole
Determination of Gastric pH
We evaluated the effect of rabeprazole, a proton pump inhibitor that reduces
stomach acid, on oral bioavailability of OJT007 in another crossover study design.
Briefly, adult male SD rats (n=4) weighing 296-338 g were cannulated through the
jugular vein under anesthesia one day prior to the study. The rats were fasted overnight
prior to and for four hours after drug administration. Water was always available to the
rats. Fasting rats were pretreated with an intravenous bolus administration of 10 mg/kg
rabeprazole (dissolved in saline) 30 minutes before each rat received a 25 mg/kg oral
dose of OJT007 cosolvent formulation. Under anesthesia, the abdominal cavity was
opened, and the stomach was located. The antrum cardiacum and pylorus of the stomach
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were ligated. An incision to the stomach wall was made and the gastric juice pH was
measured with a pH meter at 0.5, 1 and 2 hours after rabeprazole administration.
Dosing and Sampling
Fasting rats were dosed with 25mg/kg oral dose of OJT007 cosolvent formulation.
Serial blood samples (100 µL each) were collected before dose and at 0.25,0.5, 0.75, 1,
1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose. Plasma samples were separated and stored at
-80oC pending LC-MS/MS analysis of OJT007 concentrations. Urine samples were
collected up to 24 hours post dose pending LC-MS/MS analysis of OJT007. Following a
week washout period, fasting rats were pretreated with an intravenous bolus
administration of 10 mg/kg rabeprazole (dissolved in saline) 30 min before the oral
administration of OJT007 cosolvent formulation (25 mg/kg). Serial blood samples (100
µL each) were collected before OJT007 dose and at 0.25,0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10
and 24 hours post dose. Plasma samples were separated and stored at -80oC pending
analysis. Urine samples were collected up to 24 hours post dose.
3.13 Pharmacokinetic Analysis
Plasma OJT007 concentration versus time data were analyzed for each rat using a
non-compartmental model (WinNonlin v8.1, Pharsight Corp, Mountain View, CA). The
noncompartmental pharmacokinetic parameters derived after intravenous administration
were maximum plasma concentration (C0), terminal elimination half-life (T1/2), systemic
plasma clearance (CL), apparent volume of distribution (Vd), the total area under the
plasma drug concentration-time curve from 0 to last sampled point (AUCLast), the total
area under the plasma drug concentration-time curve from 0 to infinity (AUC0-∞), MRT
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•

AUC0-∞ - The area under the concentration-time curve from time zero to infinity
was calculated using the trapezoidal method using the plasma drug
concentration vs time data from time zero to the last experimental time plus the
excess area (from last experimental time to infinity).

•

T1/2 – The terminal half-life of the drug was calculated as
T1/2 =0.693/K

(12)

The terminal phase rate constant (K) was determined from the slope of the terminal
linear segment of a semilogarithmic plot of plasma drug concentration vs. time.
•

C0- Initial plasma concentration of drug was determined by back

extrapolation.
•

Vd- Volume of distribution was calculated as
Vd= Dose / (K x AUC0-∞)

•

Cl – The total body clearance was calculated as
Cl= Dose / AUC0-∞

•

(13)

(14)

MRT- The mean residence time extrapolated to infinity was calculated

using moment analysis according to the equation
MRT=AUMC0-∞ / AUC0-∞

(15)

where AUMC0-∞ is the area under the first moment curve extrapolated to infinity
and AUC0-∞.

•

Vss- The volume of distribution at steady state was calculated according to

the following equation
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Vss= Cl x MRT
•

(16)

ER- The hepatic extraction ratio calculated as the ratio of systemic clearance

(Cl) to liver blood flow (Q)
)R

ER= W

(17)

After extravascular administration, the following pharmacokinetic parameters were
calculated using phoenix WinNonlin non-compartmental analysis:
•

Tmax- Time of maximum observed concentration. It is determined by

observation of the entire concentration time- profile.
•

Cmax- Maximum observed concentration, occurring at Tmax. It is

determined by observation of the plasma- concentration time profile.
•

CL/F – The total body clearance after extravascular administration

calculated as defined above.
•

Vd/F- Volume of distribution for extravascular administration calculated as

defined above.
•

F - The absolute oral bioavailability was estimated according to the

following equation:
X% =

•

YZ[\]/^_`A a]bc
YZ[de/fg a]bc

" 100%

(18)

Frel - The relative oral bioavailability with versus without gastric acid

inhibition was calculated using the following equation:
YZ[ jdkl _`mc\_`n]Ac

h:65<9i: X% = YZ[ jdkl]ok _`mc\_`n]Ac

(19)
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•

Fh- Hepatic bioavailability calculated according to the following equation
Fh= 1-ER

(20)

3.14 Statistical analysis
Statistical results were performed using Sigma Plot v11.0 (La Joya, CA). Paired t-test at a
0.05 level of significance was used to determine statistical significance across treatments
on exposure pharmacokinetic parameters.

CHAPTER 4
RESULTS AND DISCUSSION
4.1. LC-MS/MS Method Development
The method development process entails three main tasks. First, the mass
spectrometric conditions need to be optimized to achieve the best signal-to-noise ratio for
the analyte of interest. Second, the chromatographic conditions must be optimized to
achieve the best selectivity while minimizing matrix effect. Third, the sample preparation
process must be optimized to ensure sufficient sample cleaning.
4.1.1. Mass Conditions
Positive ion mode and electrospray ionization (ESI) provided the best peak
intensity compared to the negative mode and atmospheric chemical ionization (APCI).
During Q1 scan, the presence of the analyte of interest (i.e., OJT007) was confirmed as
indicated by a pseudo-molecular ion [M+H]+ at 325.
The compound dependent parameters were optimized based on the compound
ionization efficiency and fragmentation pattern. Through Q1MI scan mode, the XIC
signal of the pseudo-molecular ion at m/z 325 was monitored, ramping the DP values
from 0-400 V. The best signal intensity was found with DP of 105 V, because it
effectively eliminates ion clusters (Figure 8).
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Likewise, the EP was set at 10 V. In a subsequent experiment, using product ion
scan, the fragmentation of the precursor ion was evaluated by ramping the CE values
from 10 to 100V. The optimal CE value for the formation of the fragment 205 was 30V
(Figure 9). Similarly, the collision exit potential (CXP) was optimized to 11 V by
ramping the value from 5-100V to ensure optimal sensitivity.
The source parameters were optimized in order to obtain the most suitable
conditions for the analyte while ensuring signal stability and sensitivity. Curtain gas
(CUR) was set at 25 psi to prevent the entrance of neutral contaminants. The ion spray
voltage was set at 4500 V to ionize sample. CAD gas was set on high for optimal
pressure of collision gas in Q2. Source temperature was set at 500. The nebulizer gas
(GS1) was set at 50 psi to ensure optimal generation of small droplets during sample
flow. The heater gas was set at 40 psi to ensure evaporation of the generated small
droplets and to prevent solvent from entering the mass analyzers.
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DP= 105

Figure 8: Optimal DP Value: XIC for 325 m/z. The apex of the XIC trend was reached at
the optimal DP value of 105 V.
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Figure 9: Optimal CE. Intensity signal obtained in MRM mode following the transition
from the precursor ion at 325 m/z to the selected product ions 205.
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4.1.2. Chromatographic Conditions
OJT007 does not have a commercially available stable isotope-labeled analog. As
such, we selected voriconazole as the internal standard, which has a similar ionization
mode, sensitivity, and lipophilicity to OJT007 (M. Li et al., 2018). Several mobile phase
compositions and columns were tested until an optimal intensity and peak shape were
attained. The best response and peak shape were achieved with an Acquity UPLC BEH
C18 column (50 × 2.1 mm, 1.7 μm) using 0.1% formic acid in acetonitrile and water as
the mobile phase. OJT007 is a weak base analyte; the addition of 0.1% formic acid to the
mobile phase aids in the formation of ions in the solution in order to achieve the optimal
response in ESI.
Figure 10 illustrates the chromatograms obtained under the established
chromatographic conditions. Although the analyte was in an ionized form, an adequate
chromatographic performance was observed. This may be due to the analyte’s
hydrophobic moiety maintaining the ability to interact with the stationary phase.
Likewise, a good peak shape may be attributed to the Acquity UPLC BEH C18 column’s
endcapping effectively eliminating unbounded silanol groups preventing ionic
interactions with the positively charged analyte.
The gradient was optimized to ensure appropriate chromatographic retention and
separation while preventing carryover. The chromatographic run time for the developed
assay was 5 min, with retention times of 2.16 and 1.74 for OJT007 and IS, respectively,
in plasma (Figure 10, A) and urine (Figure 10, B).
Potential carryover interference peaks between the injections were prevented
using an organic solvent mixture comprising 50% acetonitrile and 50% methanol as a
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needle wash between the injections. The purpose of the needle wash was that of
solubilizing any remaining analyte that adhered onto the needle. The adherence or
adsorption of analyte onto the needle has been reported as a source of carryover, which
can be prevented by optimization of needle wash during LC method development
(DesJardins et al., 2019).
4.1.3 Sample Preparation
An important component of the method development effort is sample preparation.
Often during ADME evaluations, samples consist of complex biological matrices which
contain endogenous components (i.e., proteins and lipids) which might interfere with the
detection of the drug. Basically, this interference could affect the ionization of the drug
causing variation in response. Moreover, the endogenous components can dirty and
damage the chromatographic column and the source.
As sample extraction method, protein precipitation was selected for its simplicity
and to ensure a high throughput workflow. It was tested both the efficiency of methanol
and acetonitrile at cleaning samples using different ratios of precipitant organic solvent to
plasma. Precipitant to plasma ratio of 1.5 for acetonitrile and 2.5 for methanol has been
reported to remove approximately 90% of plasma proteins (Liu & Aubry, n.d.). A
precipitant to plasma ratio of 10:1 and 5:1 yielded clear supernatants for methanol and
acetonitrile, respectively. The need for larger volumes necessary for protein precipitation
with methanol led to diluted samples, which translated into low signal intensity. The best
compromise between sample clean-up and signal intensity was found using acetonitrile.
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Figure 10: Representative chromatograms in A) rat plasma spiked at 50 ng/ml and B)
spiked rat urine at 50 ng/mL
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4.2. Method Validation
4.2.1. Linearity and Sensitivity
Linear calibration curves in rat plasma and urine were generated by plotting the
peak area ratio of OJT007 to IS against known standard concentrations of OJT007.
Because the standard curve spans several orders of magnitude, a weighting factor of 1/x
was used to construct the standard curves. Generally, unweighted regressions are used
whenever errors from the instrument response (dependent variable) are independent of
each other, uncorrelated with the dependent variable (concentration) and response have
equal variance or standard deviation across the different concentrations. However, at
higher concentrations, standard deviation and variance are larger. Consequently,
homoscedasticity is violated, and weighting is used to address the heteroscedastic error
(Gu et al., 2014).
The slope, intercept, and coefficient of determination were estimated using leastsquares linear regression method. Linear correlation coefficients greater than 0.99 were
considered acceptable for the quantification of the analyte in the biological matrix.
The lower limit of quantification (LLOQ) was evaluated based on the signal-tonoise ratio of at least 5:1. Based on a signal-to-noise ratio of at least 5:1, the LLOQ for
the developed assay was 5 ng/mL in rat plasma (Figure 11, A) and 10 ng/mL in rat urine
(Figure 11, B). The standard curves of OJT007 in plasma and urine were linear in the
concentration range of 5–1000 ng/mL (Figure 12, A) and 10-1000 ng/mL (Figure 12, B),
respectively.
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4.8

86

A)

39
35
A n alyte A rea / IS A rea

30
25
20
15

Y=0.0382x+0.238
R2=0.9990
Linear Range ̶ 5-1000 ng/mL

10
5
0
100

B)

200

300

400 500 600 700
Analyte Conc. / IS Conc.

800

900

1000

8.7
8.0

A n alyte A rea / IS A rea

7.0
6.0
5.0
4.0
3.0

Y=0.0087x+0.0251
R2=0.998
Linear Range ̶ 10-1000 ng/mL

2.0
1.0

\

0.0
100

200

300

400 500 600 700
Analyte Conc. / IS Conc.

800

900

1000

Figure 12: Representative standard curves in A) blank rat plasma and B) blank rat urine
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4.2.2 Selectivity and Specificity
Selectivity or specificity identifies the ability of the assay to quantify the analyte
in the presence of interferences present in the matrix. The acceptance criterion for
specificity and selectivity is that the peak area ratio in the blank samples should be less
than 20% of the peak areas of LLOQ samples. No significant interfering peak from
endogenous matrix was found at OJT007 and IS retention time, neither in plasma (Figure
13, A) nor in urine (Figure 13, B), indicating good selectivity and specificity.
4.2.3. Accuracy and Precision
The intra- and inter-day accuracy, presented as the percentage of relative error,
RE%; and precision, presented as the percentage coefficient of variation, CV%, are
summarized in Table 6. In rat plasma, the intraday coefficient of variation ranged from
1.96 to 8.28%, and the percentage of relative error ranged from 3.40 to 10.1% in plasma.
The inter-day coefficient of variation ranged from 3.99 to 11.5%, and the percentage of
relative error ranged from 5.45 to 9.69% in plasma.
In rat urine, the intra-day coefficient of variation ranged from 0.96% to 6.49%,
and the percentage relative error ranged from 0.09% to 8.60%. The inter-day precision in
coefficient of variation ranged from 5.72% to 8.18%, while the inter-day accuracy ranged
from 2.22% to 7.91%. The precision and accuracy were within the acceptable limit of
≤20% for LLOQ and ≤15% for the high, medium, and low QC, as established by the
FDA Bioanalysis guidance both in plasma and urine. This data indicates that the
developed LC-MS/MS method is accurate and precise for the quantification of OJT007 in
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Table 6. Intra and Inter-day Accuracy and Precision of the LC-MS/MS Assay.
Biological
Matrix

Plasma

Urine

*

QC

Nominal
Concentration
(ng/mL)

Intra-day (n=6)

Inter-day (n=6)

Accuracy
(RE, %) *

Precision
(CV, %) *

Accuracy
(RE, %) *

Precision
(CV, %) *

LLOQ

5

5.60

8.28

9.69

11.5

Low

15

10.1

3.49

5.78

7.29

Medium

75

2.88

1.96

5.52

4.58

High

750

3.40

3.03

5.45

3.99

LLOQ

10

7.33

0.96

7.91

8.18

Low

15

4.11

3.69

3.00

6.34

Medium

75

0.094

3.63

3.71

6.74

High

750

8.60

6.49

2.22

5.72

Accuracy and precision values ≤ 20% for LLOQ and ≤15% for QCs is considered
acceptable according to the US FDA Guidance on Bioanalytical Method Validation
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rat plasma and urine over a concentration range of 5–1000 ng/mL and 10-1000ng/mL,
respectively.
4.2.4. Extraction Recovery and Matrix Effect
The extraction recovery of OJT007, expressed as the percentage recovered (Table
7), was calculated as a ratio of the response obtained from a sample of the biological
matrix with OJT007 before protein precipitation to the response from sample spiked after
protein precipitation. In blank rat plasma, the mean extraction recovery for OJT007 was
95.8% at the low QC (15 ng/mL), 98.3% at the medium QC (75 ng/mL), and 91.2% at the
high QC concentration (750 ng/mL). Likewise, in blank rat urine, the mean extraction
recovery for OJT007 was 85% at the low QC (15 ng/mL), 87% at the medium QC (75
ng/mL), and 86.1 % at the high QC concentration (750 ng/mL). This data indicates that
the OJT007 extraction method from plasma and urine by protein precipitation with
acetonitrile is appropriate.
The matrix effect indicates potential ion enhancement or suppression caused by
co-eluting matrix components during LC-MS/MS analysis. A positive matrix factor value
signifies an enhancement of the analyte signal, while a negative value indicates analyte
signal suppression. No significant matrix effect is considered to have taken place if the
matrix factor is within ±15%. Table 7 shows the average matrix factors for low, medium,
and high QC concentrations of OJT007 in plasma and urine. This data suggests that the
sample preparation method successfully removes the matrix components responsible for
variability in the analyte signal intensity. Furthermore, this data suggests that the
chromatographic conditions effectively prevented ion suppression or enhancement.
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Table 7. Extraction Recovery Rates and Matrix Factors of the LC-MS/MS Method for the
Analysis of OJT007 in Rat Plasma and Urine.
Biological
Matrix

Nominal
Concentration(ng/mL)

Extraction
Recovery (mean
± SD, %)

Matrix Effect

Plasma

15

95.81± 1.54

3.79± 0.53

75

98.26± 1.74

8.73± 1.71

750

91.17± 2.38

3.40± 1.36

15

85.00± 6.84

8.73±1.89

75

87.00± 5.18

14.90±5.28

750

86.10± 7.94

12.64±2.45

Urine

*[n = 3; mean (± SD)].

(mean ± SD,
%)
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4.2.5 Stability
4.2.5.1 Stability in Plasma
Stability studies were conducted to evaluate the stability of the analyte under the
expected storage and handling conditions. The stability study results in rat plasma—
expressed as the mean remaining percentage of the nominal concentration—are
summarized in table 8.
The data in table 8 suggests that OJT007 was stable for up to 4 h in rat plasma at
room temperature, this effectively eliminates any concern regarding analyte degradation
during sample preparation. The long-term stability samples at low, medium, and high QC
concentrations were within 10% of the nominal concentration, demonstrating that
pharmacokinetic samples could be stored at −80 °C for up to 14 days without degrading
the integrity of the sample. The mean recovery of OJT007 from rat plasma following
three freeze–thaw cycles was 95.1%, 98.3%, and 96.1% at low, medium, and high QC
samples, respectively, suggesting that repeatedly freeze–thawing the plasma samples did
not influence the OJT007’s stability. The autosampler stability was expressed as the
mean recovery OJT007 from the extracted plasma placed on the autosampler for up to 24
h at 15 °C. The data demonstrate that OJT007 is stable in processed samples during
analysis conditions for up to 24 h.
4.2.5.2 Stability in Urine
Stability studies were conducted to evaluate the stability of the analyte under the
expected storage and handling conditions. The stability study results in rat urine—
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Table 8: Stability of OJT007 in Rat Plasma/Urine Samples for LC-MS/MS Analysis
Stability Test

Nominal
Concentration (ng/ml)

Short-Term Stability

15

102.44±4.44

75

97.11±3.34

750

91.42±3.91

15

96.00±4.37

75

93.78±1.39

750

94.67±3.93

15

89.56±7.70

75

97.20±8.72

750

101.6±1.85

15

95.11±0.77

75

98.33±0.40

750

96.10±1.07

(4 hr, RT)

Long-Term Stability
(14 days, -80oC)

Auto-Sampler Stability
(24 hr)

Freeze Thaw
(-80oc to RT)

* [n = 3; (mean ± SD)]

Mean Recovery%
± SD
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expressed as the mean remaining percentage of the nominal concentration—are
summarized in table 9.
The data in table 9 suggests that OJT007 was stable for up to 4 h in rat urine at
room temperature; however, the decreased mean recovery suggests the drug should be
processed in less than 4 hours upon removal from the freezer to avoid analyte degradation
during sample preparation. The long-term stability samples at low, medium, and high QC
concentrations were within 10% of the nominal concentration, demonstrating that
pharmacokinetic samples could be stored at −80 °C for up to 14 days without degrading
the integrity of the sample. The mean recovery of OJT007 from rat urine following three
freeze–thaw cycles was 88.1%, 86.7% and 85.6% at low, medium, and high QC samples,
respectively, suggesting that repeatedly freeze–thawing the plasma samples did not
significantly influence OJT007’s stability. The autosampler stability was expressed as the
mean recovery OJT007 from the extracted urine placed on the autosampler for up to 24 h
at 15 °C. The data demonstrate that OJT007 is stable in processed samples during
analysis conditions for up to 24 h.
4.2.6 Dilution Integrity
The dilution integrity was assessed by determining the accuracy and precision of
the samples diluted with blank plasma. The accuracy (RE%) was less than 7.35%, and the
precision (CV%) was less than 8.91% (Table 10). The data suggest that the concentration
of OJT007 in plasma samples of greater concentrations than the ULOQ can be accurately
and precisely quantified following up to 50 times dilution with blank plasma before the
analysis
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Table 9: Stability of OJT007 in Rat Urine Samples for LC-MS/MS Analysis
Stability Test

Short-Term Stability

Nominal
Concentration
(ng/ml)

Mean Recovery%
± SD

15

86.74±20.58

75

90.11± 5.49

750

88.09± 2.16

15

101.36±4.77

75

95.04±23.35

750

95.99±7.21

15

89.73 ±8.63

75

92.48 ± 3.54

750

93.29 ± 3.12

15

88.08± 5.62

75

86.69± 11.38

750

85.62± 11.43

(4 hr, RT)

Long-Term Stability
o

(14 days, -80 C)

Auto-Sampler Stability
(24 hr)

Freeze Thaw
o

(-80 c to RT)

* [n = 3; (mean ± SD)]
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Table 10. Dilution Integrity Accuracy and Precision of OJT007 in Rat Plasma
Biological

Nominal

Dilution

Accuracy

Precision

Sample

Concentration

Factor

(RE%)

(CV%)

(n=6)

(n=6)

5

7.35

5.67

10

6.87

3.66

20

3.77

8.91

50

7.03

4.95

(ng/ml)

Plasma

5000
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4.3 Preformulation
4.3.1 Solubility in Common Solvents
The solubility of OJT007 was evaluated in various common solvents. The
solubility of OJT007 in water, ethanol, PEG 400, labrasol, DMSO, Tween 80 was
determined by the shake flask method. Solubility in general increased with the
hydrophobicity of the solvent, so it is possible that hydrophobic interactions govern the
solubility of the drug. The results presented in figure 14 reveal that OJT007 has poor
solubility in compounds with a high dielectric constant, as exemplified by the solubility
of <0.5 mg/ml in water and 1.08mg/ml in ethanol. The dielectric constant is an index of
solvent polarity. Nonetheless, polarity alone doesn’t explain the poor solubility of
OJT007 in water as OJT007 is very soluble in DMSO (>20mg/ml). DMSO is a polar
aprotic solvent, which means it does not act as a proton donor. Thus, it is possible that
this characteristic prevents OJT007 from being highly soluble in ethanol or water.
4.3.2 pH solubility
The aqueous solubility of OJT007 was assessed at various pH using standard
buffer solutions of pH 1.2-7, representing the range of pH encountered through the GI
tract. The dissolution media were sampled after 24 hours and quantified via UPLC for
OJT007 dissolved. The pH solubility data is presented in figure 15.
OJT007 is more soluble at acidic pH. OT007 is an ionizable drug in aqueous solution
because it contains a basic and acidic functional group. It can exist either as an uncharged
or charged form. The drug in solution with a pH below its basic pKa (3.3) will get
converted into the ionized form, making it a more soluble moiety.
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Figure 14. OJT007 solubility in various solvents at room temperature
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Figure 15: OJT007 pH solubility
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4.3.3

Solution State pH Stability
Orally administered drug encounters through GI tract a varied pH environment.

As such, we decided to evaluate the effect of varying pH conditions on the drug by
incubating OJT007 respectively in buffers of various pH prepared according to United
States Pharmacopeia (USP) guidelines. Figure 16 panel A shows a representative
chromatogram of OJT007 at a wavelength of 254 nm. After incubation under acidic
conditions, two new peaks eluting at 1.732 and 2.292 minutes were observed at that same
wavelength (Figure 16, panel B).
Figure 17 depicts the stability of OJT007 under different pH. Degradation was
rapid at pH 1.2-3, and by 0.5 hours 50% or less remained of the drug. Likewise, by 2
hours 20% or less remained of the drug for pH 1.2-5. Therefore, there is a clear relation
between pH and drug stability: the lower the pH, the higher the degradation. These results
suggest that OJT007 is likely to be unstable on stomach pH and special formulation
considerations must be accounted.
We hypothesize that this is caused due to OJT007 being a Schiff base. OJT007
contains an imine functional group that could be prone to acid-catalyzed hydrolysis
(Scior & Garces-Eisele, 2006). Figure 18 shows the proposed degradation pathway in
OJT007 based on the drug structure. In the hydrazone cleavage catalyzed by acidic pH, a
proton attacks the imino nitrogen atom leading to the hydrolysis of the imino-carbon
bond. The result of this hydrolysis is an aldehyde and a hydrazine.
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OJT007
DP1

DP2

DP1

DP2

OJT007

Figure 16: A) Representative chromatogram for OJT007 at 254 nm. B) Representative
chromatogram and Spectra for OJT007 at 254 nm after 1 hour incubation at pH 1.2
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Figure 17: Stability of OJT007 at pH 1.2-10.

Figure 18: Proposed degradation mechanism: Hydrazone hydrolysis of OJT007.
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4.3.4

PKa measurement
The pKa values for OJT007 were measured using the UV-metric method with the

SiriusT3 and compared to the pKa values calculated by ACD/ChemSketch. For the UVmetric method to be successful, the ionizable groups must be located near a chromophore
such that changes in protonation state will modulate the UV absorbance spectra. For
OJT007, three pKa values were calculated by ACD/ChemSketch 8.7 (acid), 5.8 (base)
and -3.3 (base). This latter pKa is outside the operating range in the SiriusT3. The Sirius
T3 measured 10 (acid) and 3.3 (base).
4.3.5

Cosolvent formulation
The ideal vehicle for intravenous dosing is normal saline. Nonetheless, using

saline alone was not an option for this project due to OJT007 low water solubility. The
low solubility of OJT007 can be improved by incorporating it into a water-miscible
cosolvent in which it has a good solubility. An important consideration during the
formulation of OJT007 was preparing a formulation with a reasonable concentration to
ensure that during drug administration, animals were not dosed more than 5 mL/Kg (IV
Bolus) or 10 mL/Kg (PO). Furthermore, a cosolvent system suitable for intravenous
administration must resist precipitation of the drug upon dilution with intravenous (IV)
fluids or blood.
Various co-solvent systems with varying compositions and ratios of solvents were
prepared and evaluated with OJT007 concentrations ranging from 1 – 10 mg/mL. Based
on the solubility data, DMSO, PEG 400, Tween 80, and labrasol were selected as
potential cosolvents for the formulation. The robustness of each system was tested by
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diluting with different ratios of normal saline or water to evaluate OJT007 precipitation
within 12 hours. The optimal cosolvent formulation was found to be PEG 400 57%,
Tween 80 29%, DMSO 14%. This formulation is to be diluted with normal saline or
water to a final concentration of 2.5 mg/mL
4.4 Plasma Protein Binding (PPB)
The plasma protein binding of OJT007 was evaluated at different concentrations
using the ultrafiltration method. The fraction of OJT007 bound to plasma protein binding
had a mean value of 99.11±1.18%. Binding to plasma proteins is affected by the chemical
structure of the drug, the pKa of the substance, and the pH of plasma. Possibly, OJT007
binds preferentially to alpha-1 acid glycoprotein, given its basic nature.
OJT007 high PPB values may have implications on the drug disposition. PPB plays
a crucial role in the pharmacokinetics and pharmacodynamics of drugs. Free drug
hypothesis states that only unbound drug is available at the site of action for
pharmacological activity (Bohnert & Gan, 2013). Drug molecules in vivo are bound
reversibly to proteins in plasma (and in tissues), or they are unbound. Free drug
molecules diffuse across the membranes to interact with the intended therapeutic target or
other sites other than the therapeutic target, which could cause toxicity. Thus, PPB
influences the distribution of a drug from blood to tissues and from tissues to site of
action.
High plasma protein binding may predispose OJT007 to drug-drug interactions when coadministered with other high plasma protein-bound drugs due to drug displacement.
Drug-drug interactions may have clinical implications in terms of efficacy and exposure
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for drugs with narrow therapeutic index intravenously administered and for high
extraction ratio intravenously administered drugs (Benet & Hoener, 2002). Following
intravenous administration, total drug clearance is independent of plasma protein binding
for high extraction drugs (CL= QH). Although average total drug concentrations and AUC
are unaffected by changes in protein binding (AUCIV= Dose/ QH), unbound drug
concentrations are proportional to changes in plasma protein binding. (AUCUnbound IV = fU
x AUCIV )(Benet & Hoener, 2002; Smith et al., 2010).
4.5 Metabolism of OJT007 in CYP and UGT reaction systems
CYP450 is a superfamily of enzymes that is responsible for the metabolism of most
marketed drugs, and UDP-glucuronosyltransferases (UGT), is an enzyme family that
conjugates the sugar molecule UDPGA to alcohols, acids, and basic amines. Both UGTs
and CYPs represent more than 80% of the metabolic pathways of drugs (B. Wu et al.,
2011); Thus, we evaluated CYP and UGT mediated metabolism of OJT007.
4.5.1

CYP Mediated Metabolism
Before incubation, a single peak eluting at 3.269 minutes corresponding to

OJT007 was observed in UPLC analysis (Figure 19, A). After incubation, three
additional peaks were observed at retention times of 2.041, 2.583, and 2.946 minutes in
UPLC analysis (Figure 19, B). The UV spectra of these additional peaks were similar to
that of OJT007, suggesting that the skeleton of these metabolites is similar to that of
OJT007 (Figure 19, C).
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`Table 11. Plasma Protein binding of OJT007 in Rat Plasma
Concentration
(μg/mL)

Bound Fraction
(%) ± SD
(n=3)

50

99.73±0.30

75

99.84±0.50

100

97.75±1.83
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A)
OJT007

B)

Metabolite

OJT007

C)

Figure 19: A) Representative chromatogram of OJT007 B) Representative
chromatogram of OJT007 and oxidation metabolites. B) UV spectra of OJT007 and
oxidation metabolites

108

4.5.1.1 Oxidation Metabolite Identification
LC-MS/MS Identification of Oxidation Metabolites
LC-MS/MS analysis was used to confirm the identity of the newly eluted peaks.
Targeted metabolite identification takes advantage of the extensive understanding of
metabolic enzymes and the metabolic pathways they could contribute. Hydroxylation
reactions are very common in drugs containing aromatic rings or aliphatics (saturated or
unsaturated in their chemical structure (Zhu et al., 2017). Q1MI scan (Figure 20, A-C)
identified a pseudo-molecular ion at m/z 341, indicating hydroxylation at 1.66, 1.74 and
1.96 minutes.
In neutral loss scan, ions are scanned on Q1, fragmented in Q2, and then Q3 scans
changes in mass which correspond to a set neutral loss. In other words, neutral loss scan
displays the spectrum of all parent ions which lose a selected neutral loss fragment. From
the product ion spectrum of OJT007 standard, the main product ion is m/z 205,
corresponding to the loss of 120 Da. Thus, we performed a neutral loss scan for 120. This
procedure (Figure 21) indicated the presence of OJT007 itself with an m/z of 325, plus
one metabolite which eluted at 1.74 minutes with an m/z of 341. This finding confirmed
that the peak eluting at 1.74 minutes corresponds to a mono-oxidative metabolite. In
addition, this suggests that the oxidation occurs in the 5,6,7,8Tetrahydro[1]benzothieno[2,3-d]pyrimidin-4-amine portion of the molecule.
A NL scan (Figure 22) was then performed for 136 Da (120 plus 16) to screen for
metabolites obtained by hydroxylation on the neutral fragment. Neutral loss scan
evidenced three peaks eluting at 1.78, 1.96 and 2.17 minutes(Figure 22, A). NL spectra
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for the peaks eluting at 1.78 (Figure 22, B), and 1.96 (Figure 22, C) showed ions with m/z
341, which is 16 Da higher than the addition ion of OJT007, confirming both peaks to
belong to metabolites. The neutral loss scan suggests that oxidation for the metabolite
eluting at 1.96 occurs in the phenol portion of the molecule. On the other hand, it is
possible that the same neutral loss that gave rise to the peak at 2.16 (parent molecule),
gave rise to the peak eluting at 1.78 minutes. Interestingly neutral loss scan did not show
the presumed metabolite at 1.66 min, which could possibly indicate hydroxylation does
not occur at the phenol ring.
Precursor ion scans yield as a result the spectrum of all parent ions which produce
the same product ion in their spectrum. As such, a precursor scan for m/z 221 (m/z
205+16) was performed as this would indicate the presence of a metabolite hydroxylated
in the 5,6,7,8-Tetrahydro[1]benzothieno[2,3-d]pyrimidin-4-amine portion (bottom half)
of the molecule. Figure 23 shows a peak at 1.74 and abundant ions at m/z 341 suggesting
hydroxylation occur in the bottom half of the molecule. In addition, this precursor ion
scan confirms the observed neutral loss of 120.
As a final confirmation step, product ion analysis (figure 24, A-D) showed a
pseudo-molecular ion for the metabolites at m/z 341 [M+H]+, which is 16 Da higher than
that of OJT007 (which is m/z 325), indicating hydroxylation. The spectra for the peak
eluting at 1.66 (Figure 22, B) shows a major fragment at 221, which is 16 Da higher than
the major fragment for OJT007. A similar major fragment at m/z 221 was observed for
the peak eluting at 1.74 minutes. This fragmentation suggests that hydroxylation occur
potentially in the bottom half of the molecule. The MS/MS spectra for the peak eluting at
1.96 (Figure 24, D) MS/MS spectra show a major fragment at m/z 205, which is similar
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to the major fragment ion of OJT007. Likewise, the spectra for the peak eluting at 1.96
shown a fragment at 138, suggesting that hydroxylation potentially occur in phenol ring.
In MRM at m/z at m/z 341 → 221(Figure 25), the high intensity for the peaks eluting at
1.66 and 1.74 may further confirm hydroxylation occur on the bottom half of the
molecule. Based on these spectra, in figure 26 we have proposed possible metabolite
structures. The proposed structure for M1 and M2 comprehend a mono-hydroxylated
metabolite with hydroxylation occurring on the bottom half of the molecule while the
proposed structure for M3 corresponds to a mono-hydroxylated metabolite with oxidation
occurring in the aromatic ring portion of the molecule.
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Figure 20: Q1MI Spectra for OJT007 oxidation metabolites A) 1.66 min B) 1.74 min and
C) 1.96 min
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for M2
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Figure 22: Neutral loss of 136 A) chromatogram and Spectra at B) 1.74 minutes C) 1.96
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Figure 23: A) Precursor ion scan of 221 Da chromatogram. B) PI scan spectra for M2
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Figure 24: A) MS/MS Chromatogram. B) MS/MS Spectra of M1. C) MS/MS Spectra of
M2. D)MS/MS Spectra of M3.
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341 → 221
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Figure 26: Proposed Structure for M1, M2 and M3.
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4.5.1.2 Metabolic Stability of Oxidation Metabolites
In a typical microsomal stability assay, protein concentrations are kept below 2
mg protein/ml (to prevent nonspecific binding) with incubation times below 1 hour (to
prevent loss of enzyme activity). In addition, measuring the depletion of the parent drug
entails at least 10-15% turnover to make a reliable measurement. This requirement is
based on the bioanalytical method having accuracy and precision values within that range
(Di & Obach, 2015).
In our study, OJT007 displayed no significant turnover of the parent drug with
enzyme concentration below 10 mg protein/ml; thus, we used a high enzyme
concentration. In figure 27 are shown the levels of OJT00 remaining after incubation with
SD rat liver microsomes for different times. The biphasic profile is due to loss of enzyme
activity due to long incubation time. Nonetheless, incubation for less than 1 hour yielded
insufficient metabolism to conclude metabolic turnover. Furthermore, substrate depletion
was observed in the incubation without cofactor; However, this may be attributed to the
instability of OJT007 at pH of 7.4, which is consistent with our pH stability results.
For screening purposes, the metabolic half-life was determined using a single time
point analysis (Di et al., 2004) based on first-order reaction kinetics. The equation for the
calculation of half-life from % remaining of the parent at a given time is shown in
equation 8.
The half-life for OJT007 is 1.28 hour making OJT007 a stable compound (Słoczyńska et
al., 2019). The CYP metabolic screening results suggested that Phase I metabolism,
though happening, may not be playing an important role in OJT007 metabolism.
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4.5.2

UGT Mediated Metabolism
Rapid conjugation in the intestine and liver is primarily responsible for the poor

oral bioavailability of phenolics. Glucuronidation of phenolics generally occurs at the
nucleophilic –OH attached to the aromatic ring (O-glucuronidation). In an OJT007
molecule, there is one hydroxyl group that may serve as the glucuronidation site. Thus,
we evaluated glucuronidation in OJT007.
Figure 28, panel A shows a representative chromatogram of OJT007 before
microsomal incubation. After microsomal incubation, an additional peak was observed at
2.020 minutes (Figure 28, A). The UV spectra of this newly eluted peak were similar to
that of OJT007 (Figure 28, B), suggesting that the skeleton of the additional peak was
similar to that of OJT007. This newly eluted peak is tentatively identified as OJT007
glucuronide.
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Figure 27: Metabolic stability of OJT007. Levels of OJT007 remaining after incubation
with SD rat liver microsomes for various times shown as % of starting amount at time 0
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Figure 28: A) Representative chromatogram of OJT007. B) Representative
chromatogram of OJT007 and glucuronidation metabolite. B) UV spectra of OJT007 and
glucuronide metabolite.
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4.5.2.1 Glucuronide Metabolite Identification
LC-MS/MS Identification of Glucuronide Metabolites
Q1 multiple ions (Q1MI), neutral loss (NL), product ion (MS/MS) scan and
precursor ion scan (PI) in positive mode were used to identify the metabolite. In Q1MI
scan, Q1 works in selected ion monitoring (SIM) by selecting a specific m/z value. Q1MI
spectra (Figure 29) confirm the presence of the glucuronide metabolite as indicated by
the presence of a pseudo-molecular ion at m/z 501.2, which is 176 Da higher than that of
OJT007 at m/z 325.
In neutral loss (NL) scan, molecules which pass through Q1 and, after
fragmentation in Q2 lose a neutral molecule of 176, are transmitted through Q3 for
detection. Figure 27 shows the chromatogram and spectra obtained after a neutral loss
176. For the NL of 176 Da, the peak eluted at 1.37 minutes (Figure 30, A) had a
precursor ion at m/z of 501 as shown in the spectra (Figure 30, B), which confirms the
presence of a glucuronide.
The MS/MS spectra (Figure 31) show a pseudo-molecular ion of the conjugation
metabolite at m/z 501.2. This is 176 Da higher than that of OJT007 at m/z 325, indicating
the presence of glucuronic acid. Also, it showed major fragment ions at m/z 325, which is
the mass of the addition ion of OJT007 at m/z 325. This spectra data confirms the newly
eluted metabolite corresponds to a mono-glucuronidated OJT007.
Based on the NL scan results and the MS/MS spectra we performed a precursor
ion scan with m/z 325 to further confirm the identity of the glucuronide.
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Figure 29: A) Q1MI Chromatogram for m/z 501. B) Spectra for OJT007 glucuronide.
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Figure 30. A) Neutral loss at m/z 176 chromatogram. B) Spectra for OJT007
glucuronide.
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Figure 31. A) MS/MS Chromatogram. B) MS/MS Spectra for m/z 501 OJT007
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Figure 32 confirms that the peak eluting at 1.40 minutes corresponds to OJT007
glucuronide with m/z 501.
Hydrolysis using β-glucuronidase
Figure 33 shows the hydrolysis of the OJT007 glucuronides, which were produced
from the liver microsomes by β-glucuronidases. After incubating with β glucuronidases
from E. Coli for two hours, the OJT007 concentrations increased at least 5-fold when
compared with the control (Figure 33, A), whereas OJT007 glucuronide residuals
dramatically decreased (Figure 33, B). This chemical data confirms that the newly eluted
peak is OJT007 glucuronide.
4.6

Conversion Factors (K) of Extinction Coefficient
The glucuronidation reaction was performed at three different concentrations (2,

10, and 50 μM) to calculate average K values. The results showed that the K value for
OJT007 glucuronide was 1.06. This conversion factor was used to calculate the
concentration of OJT007 glucuronide using the standard curve for OJT007.
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Figure 32. (A) Precursor ion scan m/z 325 Chromatogram and (B) PI Spectra for
OJT007 glucuronide
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Figure 33. Hydrolysis of OJT007 glucuronide generated by rat liver microsomes with
E.Coli β-glucuronidase. Each data point indicated the mean ± SD.
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4.7

Glucuronidation rate of OJT007
Before a drug reaches the liver, it must first escape metabolism in the gut; thus,

both intestinal and hepatic glucuronidation may contribute to in vivo disposition of oral
OJT007. Therefore, the glucuronidation rates of OJT007 were determined using Rat
Liver and intestine microsomes. As shown in figure 34, the rate of formation is higher in
liver microsomes than in intestine microsomes; However, rates are similar, suggesting
that OJT007 would be glucuronidated by UGTs in the intestine as well. This has
important implications on the in-vivo oral bioavailability for OJT007 because it is
possible that absorbed OJT007 would be first metabolized in the intestine with smaller
amounts reaching the liver to be further metabolized.
We also examined species-specific differences in the glucuronidation of OJT007
in human and rat liver microsomes. Although animals have UGTs orthologous to those in
humans, these generally display different substrate specificity, tissue distribution, and
efficiency of these enzymes. As shown in figure 35, the glucuronidation rate of OJT007
at substrate concentrations of 15 μM shows the species differences between HLMs and
RLMs. This result is not surprising because each species has different UGT enzymes, and
UGT enzymes from different species have different substrate specifics. Further studies
are required to confirm this difference and to find a suitable in vivo model for future
pharmacokinetic studies.

134

Figure 34. Rate of formation of OJT007 glucuronide catalyzed by Rat liver and intestine
microsomes at the substrate concentration of 15 μM (0.5 mg protein/ml). Each data point
indicates the mean ± SD for triplicate samples
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*

Figure 35. Glucuronidation rates of OJT007 glucuronide catalyzed by liver microsomes
Sprague Dawley and human liver microsomes at the substrate concentration 15μM (0.5
mg protein/ml). Each data point indicates the mean ± SD for triplicate samples. *
Significant difference, p < 0.05
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4.8

Kinetics of OJT007 Glucuronidation
The OJT007 glucuronidation rate was determined by measuring the amount of

metabolite formed in microsomes divided by the reaction time and protein
concentrations. The substrate concentration evaluated ranged from 1.25−100 μM, with a
protein concentration of 0.035 mg of protein/mL and an incubation time of 60 minutes.
The most appropriate model was selected based on the visual inspection of the EadieHofstee plot (Figure 36). Quantitative analysis showed that the substrate concentrationglucuronidation velocity curves followed Michaelis-Menten Kinetics (Figure 36). The
Maximal metabolic rate and the Michaelis Menten constants were 1.125 nmol/min/mg
and 10.73 μM.
The rate of OJT007 glucuronidation was rapid via liver microsomes with an
intrinsic clearance value similar to those of isoflavones, a class of compounds with
limited oral bioavailability due to extensive metabolism (Chen et al., 2005). It is possible
that extensive glucuronidation may have implications in the in vivo oral bioavailability of
OJT007.
4.9 Prediction of In Vivo Clearance
To predict the in vivo clearance, the microsomal protein per gram of liver value
was used as a scaling factor to calculate the intrinsic clearance in vivo from the in vitro
intrinsic clearance. In addition, the in vivo hepatic clearance was estimated using the
well-stirred hepatic clearance model (Obach, 1999) The calculated in vivo intrinsic
clearance and hepatic clearances were 210.6 ml/min/mg and 43.61 ml/min/Kg,
respectively. The estimated hepatic clearance closely approaches liver blood flow in rats
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R2= 0.97

Apparent Enzyme Kinetics
Vmax (nmol/min/mg)

1.125

Km (μM)

10.73

In vitro Clint (μL/min/mg)

116.96

Figure 36. Apparent enzyme kinetics of OJT007 glucuronidation
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(55mL/min/Kg) (Davies & Morris, 1993), which would make OJT007 a moderate to high
extraction ratio drug.
4.10 Pharmacokinetic Studies
4.10.1 Oral Bioavailability
Intravenous Pharmacokinetics
In this study, a group of adult male Sprague-Dawley rats (n=5) received a single
dose of 5 mg/Kg IV bolus dose of OJT007. The dose amount was selected based on a
pilot study using one SD rat which received a single dose of 10 mg/Kg. From the pilot
study, it was found that at 10 mg/Kg, the rat was lethargic; Thus, the dose was decreased
by half. At 5 mg/Kg, no animal distress was observed, and adequate plasma
concentrations were achieved.
Serial blood samples (100 µL) were collected before dose and at 0.033, 0.083,
0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 24 hours. The sampled blood volume per time point
was 100 µL to ensure blood draws from the animal were less than 10% of total blood
volume. The sampling times were selected to ensure an appropriate characterization of
the profile based on the pilot study. An important consideration in sampling time points is
to ensure collecting at least three consecutive points in the elimination phase for the halflife calculation and 3-5 time points per phase. The OJT007 plasma concentration was
quantified using LC-MS/MS. Urine samples were collected up to 24 hours post-dose, and
the amount of OJT007 excreted unchanged was quantified by LC-MS/MS.
Non-compartmental and compartmental analysis using Phoenix WinNonlin was
used to generate the pharmacokinetic parameters describing the in vivo disposition of
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OJT007 after IV administration. The fitness of the pharmacokinetic model was
determined using in-built diagnostics of WinNonlin software, Akaike Information
Criterion (AIC), by plotting the predicted curve as a function of time with the observed
concentrations overlaid on the plot indicating a close correlation of the values and the
reported variability in the parameter values (Coefficient of variation, standard deviation).
The standard deviation and coefficient of variation estimated for each parameter provide
an estimate of how well the data is described by the parameters of the specified model. A
large CV% (>20%) would indicate an improper model. Discrimination between models is
driven by the minimization of the weighted squared residuals (WSS). Basically, the
model with the lowest value of WSS and AIC is considered a better model.(Rudek et al.,
2014). Based on these criteria, a two-compartment model was selected as the best fit.
The 2-compartment model used to estimate the in vivo PK parameters of OJT007 is
described by the following equation:
Ct = Ae-αt + Be-βt

(21)

Where A and B are the coefficients of the alpha and beta phases, respectively. α and β
are the elimination rate constants in the distribution and elimination phases, and Ct is the
plasma concentration of OJT007 at time t.

Weighting of 1/Y2 was applied to

compartmental analysis.
Table 12 shows the plasma concentrations observed after IV bolus administration of
OJT007. Figures 37 and 38 show the plots generated for 2-compartmental and noncompartmental analysis, respectively. On the other hand, table 13 provides the mean PK
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parameter estimates from both analyses. From figure 33, it is shown that the data fits a 2compartment model adequately.
OJT007 displayed a biexponential disposition after intravenous administration, with a
rapid distribution to the tissue compartment within the first 2 hours, followed by a slow
elimination. The initial concentration after IV administration had a mean value of 3601
ng/ml, which is 30 times above the reported in vitro EC50 values of 162.2 ng/mL for
OJT007 (Rodriguez et al., 2020).
The half-life of the distribution phase (T1/2α) was estimated to be 0.19 hr., while the
half-life of the terminal (elimination) phase had a mean value of 2 hours. The mean
volume of distribution at steady state (Vss) was 7.77 ± 3.57 L/hr/Kg while a lower volume
of distribution at steady state was calculated using compartmental analysis. This volume
of distribution was greater than the total body water in rats (Davies & Morris, 1993),
possibly due to drug partition into tissues. OJT007 is an amphoteric drug; however, at
physiological pH, it is unionized. Thus, tissue binding would be directly related to drug
lipophilicity (Smith et al., 2015).
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Table 12. Plasma Concentration in ng/mL After Intravenous Dose of 5 mg/Kg OJT007 to
Rats
Rat A

Rat B

Rat D

Rat E

Rat F

1

1

2.5

2.5

2.5

0.357

0.350

0.328

0.332

0.327

Loading
Solution
Concentration
(mg/mL)
Animal
Weight (Kg)
Dosing
Volume (mL)
0.033333

1.79

1.7

0.66

0.67

0.65

3750

2195

2160

2350

2340

0.083333

2970

1140

1480

1110

1240

0.25

1910

965

1040

677

865

0.5

1770

575

772

646

610

1

918

351

595

415

535

1.5

639

266

354.5

348

320.5

2

423

229

292

331

308

4

200

95.9

126

159

165

6

96.5

52.2

60.3

67.7

63.5

8

44.3

16.3

41.7

42.7

40.2

10

31.6

7.59

18.8

24.7

22

24

23.9

<5

7.43

9.99

9.54
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Figure 37. Individual plots (A-E) of OJT007 after IV bolus dose of 5 mg/kg using 2compartmental analysis
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Figure 38. Individual plots (A-E) of OJT007 after IV bolus dose of 5 mg/kg using Non
compartmental analysis
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Table 13. Mean Pharmacokinetic Parameters of OJT007 Following an IV bolus Dose of
5 mg/Kg
PK Parameters (Units)

Mean ± SD

Mean ± SD

NCA

2-Compartment

Route of Administration

IV

IV

N

5

5

Dose

5 mg/kg

5 mg/kg

Cmax (ng/mL)

-

2919 ±1142.7

C0(ng/mL)

3601 ±591.72

-

T1//2α (hr)

-

0.19 ± 0.15

T1/2β (hr)

-

2.00 ± 0.21

AUC0-∞ (hr.ng/mL)

2061.31 ± 240.8

2310.2 ± 791.4

t1/2 (hr)

2.12 ± 0.40

-

Cl (mL/hr/kg)

2278.3 ± 609.9

2333.5 ± 640.7

Vz (mL/kg)

6898.9 ± 1902.5

-

V2 (mL/kg)

-

3533 ± 1567

Vss (ml/kg)

7773.1 ± 3565

5446.1 ± 1528

MRT (hr)

2.25 ± 0.33

2.33 ± 0.33
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The mean systemic clearance (CL) was 2.3 L/h/kg, which accounts for about 68%
hepatic blood flow (Davies & Morris, 1993). Since the systemic clearance of a drug after
intravenous administration reflects hepatic elimination, we can calculate the hepatic
extraction ratio by taking the ratio of systemic clearance to liver blood flow (Benet, 2010;
M. Rowland, 1972). The extraction ratio (ER) for OJT007 is 0.69, which would make
OJT007 a moderate to high extraction ratio drug (Benet & Zia-Amirhosseini, 1995). A
good correlation was observed between the predicted hepatic clearance obtained from the
in vitro studies (2.61 L/hr/Kg) and the observed in vivo clearance in rats.
The mean area under the plasma concentration–time curve extrapolated to infinity
(AUC0→∞) were 2.06 mg.h/L (NCA) and 2.31 mg.h/L (2-Compartment). The mean
percentage of the dose excreted unchanged in urine after 24 hours was 0.39%, suggesting
extensive metabolism, which would be consistent with our in vitro studies.
OJT007 glucuronide was detected in vivo after IV administration. For instance,
excretion of the glucuronide in urine was detected at 24 hours. Likewise, the glucuronide
was detected in plasma. Figure 39 shows a representative plasma chromatogram at 1 hour
after IV administration. The glucuronide metabolite elutes at 1.42 minutes, while at 2.17
minutes is shown the OJT007 parent peak. On the other hand, the oxidation metabolites
identified in vitro were not found in rat plasma and urine samples. It is possible that the
oxidation metabolites undergo glucuronidation as well; thus, oxidation metabolites were
not detected. Nonetheless, our in vitro studies suggested oxidation was not a very
significant pathway.
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XIC of +MRM (4 pairs): 325.000/205.000 Da ID: OJT007 from Sample 2 (60min G21) of PK_GHIJ_21.wiff (Turbo Spray)
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Figure 39. Representative MRM chromatogram of rat plasma sample at 1 hour. Peak
eluting at 1.46 minutes is OJT007 glucuronide.
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Oral Pharmacokinetics
The oral pharmacokinetics of OJT007 was evaluated by administering a dose of
10 mg/Kg OJT007 cosolvent formulation through oral gavage to the adult male SD rats.
Serial blood samples (100 µL) were collected from each rat before dose and at 15, 30, 45,
60, 90 minutes, and 2, 3, 4, 6, 8, 10, and 24 hours post-dose. These sampling time points
were selected to ensure an appropriate characterization of the pk profile. In other words,
we were ensuring at least 3 points before the tmax and at least three points to describe the
terminal phase. The plasma concentrations obtained after oral administration are
summarized in table 14.
The pharmacokinetic parameters for OJT007 were computed using WinNonlin
v8.3 via non-compartmental and compartmental analysis. The most suitable
compartmental model and the most suitable weighting scheme were selected following
the same criteria followed after IV administration.
The pharmacokinetics observed after intravenous administration suggested a twocompartment model described the disposition for OJT007; However, based on the abovedescribed criteria, a one-compartment model and no lag time was selected for the
compartmental analysis of the data. After oral administration, a drug following a twocompartment model would be described by the Loo-Riegelman method (Equation 22),
while a drug following a one compartment model would be described by the WagnerNelson method (Equation 23)
Ct = Ae-αt + Be-βt+ Ce-Kat
x (02(0C3yz))

Where A= M(zy{)(zy02)

(22)
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Table 14. Plasma Concentration in ng/mL After Oral Dose of 10mg/Kg OJT007 to Rats
Time (hr)

Rat A

Rat B

Rat D

Rat E

Rat F

Loading Solution

1

1

2.5

2.5

2.5

0.292

0.355

0.300

0.309

0.309

2.9

3.6

1.2

1.23

1.24

0.25

10.2

6.42

27

31.4

17.5

0.5

29.2

18.72

62.1

58.2

36

0.75

40.2

29.9

62.8

88.5

67.9

1

48.7

42.9

67.8

96.7

68.9

1.5

86.4

96.9

68.9

98.1

67.9

2

81.2

60.6

65.1

96.6

63.9

3

72.6

52.9

61.4

96.7

62.7

4

49.4

38

51.7

71.2

56.1

6

26.6

26

45.1

66.7

28.1

8

12

10.1

16.6

24.6

14

10

5.98

8.2

14.6

12.7

6.94

24

<5

<5

<5

<5

<5

Concentration (mg/mL)
Animal Weight
(Kg)
Dosing Volume
(mL)
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x (02(0C3y{))

B=

C=

M(zy{)({y02)

x (02(0C3y02))
M({y02)(zy02)

K21 is the micro rate constants out of compartment 2 in a two-compartment
model. α and β represent disposition constants describing distribution and elimination in a
two-compartment model
Ct =

x

.0

M(0 y0 )

(e-kat + Be-ket)

(23)

Where Ka (absorption rate), Ke (elimination rate), and V is (volume of distribution)
In our study, seemingly, a term in the two compartment oral equation (equation 22)
“vanished”. A similar phenomenon has been discussed by others. (Nielsen-Kudsk et al.,
2009; Ronfeld & Benet, 1977). The first-order absorption rate constant (Ka) determined
in the oral animal studies is considerably lower than the α-values obtained after
intravenous studies. As the Ka values are lower than K21 values obtained using a twocompartment value after IV administration (K21= 1.82), the coefficient of the exponential
becomes negative; thus, disposition is described by a one-compartment model. The
pharmacokinetic parameters for OJT007 after oral administration are summarized in table
14. Figure 40 and 41 summarizes the plots generated after compartmental and noncompartmental analysis of OJT007. A high degree of agreement between elimination
rates after the two routes of administration in SD rats was observed.
A maximum plasma concentration of 83.84 ng/mL attained at 1.4 hours was observed
after oral administration. Although this concentration is below the EC50, many in vitro
assays overexpress the target protein to enhance assay sensitivity, which translates into
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higher EC50. In this case, efficacious drug concentrations can be significantly lower than
the in vitro activity(Smith et al., 2010). Further studies are required to assess whether the
current dosing regimen is efficacious. OJT007 has an oral absorption half-life of 0.98 ±
0.34 hours. The area under the curve, which indicates the extent of absorption or
exposure, was found to be 451.01 ± 116.92.
The absolute oral bioavailability of OJT007 was calculated using the following
equation:
Fabs = (AUC) PO / (Dose) PO
(AUC) IV / (Dose) IV

OJT007 has an oral bioavailability of 10.9 ±2.47%. To get an intuition behind the
attenuation of oral bioavailability, we looked at the kinetic expression of bioavailability.
Assuming that during GI transit drug does not degrade after oral administration,
bioavailability is the product of three availability factors F= Fabs. FG. FH, where Fabs is the
fraction of the administered drug that is absorbed into the gut wall. FG is the fraction that
gets through the gut wall unchanged, while FH is the fraction that passes through the liver
and into the systemic circulation unchanged.
In our intravenous studies, we found that the extraction ratio (ER) for OJT007 is 0.69.
We can calculate the hepatic availability using Rowland’s prediction of first-pass hepatic
metabolism FH=1-ER (M. Rowland, 1972). Thus, the hepatic bioavailability of OJT007 is
only 31%. This would mean the great majority of a dose would be metabolized in the
liver on its first pass prior to reaching the systemic circulation. A bioavailability of 31%
would be expected, assuming no drug degradation, complete absorption in the gut, and no
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gut metabolism. However, since bioavailability is only 10.9%, a fraction of the dose may
be lost due to degradation or an incomplete absorption in GI mucosa (Fabs) and/or gut
wall metabolism (which in turn affect FG).
Some authors argue that generally, the contribution of gut metabolism is negligible
compared to liver metabolism; this would, in turn, simplify the kinetic expression of
bioavailability to F= Fabs. FH (Lin et al.,1999 ). Nonetheless, significant contributions of
gut wall metabolism have been reported for several substrates (Jones et al., 2016;
Takahashi et al., 2016). A contribution of gut wall metabolism would be consistent with
our in vitro studies which suggested intestinal UGTs may play an important role in the
metabolism of OJT007, and thus in the oral bioavailability. Further studies are warranted
to confirm the contribution of Fabs and FG to oral bioavailability experimentally.
The percentage OJT007 excreted unchanged in the urine at 24 hours after oral
administration ranged from 0.034% to 0.794%, suggesting extensive metabolism. In our
in vitro studies, we identified four possible metabolites: three oxidation metabolites and
one glucuronide. Although OJT007 glucuronide was detected in urine and plasma
samples, the oxidation metabolites identified in vitro were not detected in rat plasma or
urine. Figure 42 shows a representative urine chromatogram for OJT007. OJT007
glucuronide elutes at 1.4 minutes, while OJT007 elutes at 2.16 minutes.
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Figure 40. Individual plots (A-E) of OJT007 after PO dose of 10 mg/kg using 1compartmental analysis
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Figure 41. Individual plots (A-E) of OJT007 after PO dose of 10 mg/kg using non
compartmental analysis
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Table 15. Mean Pharmacokinetic Parameters of OJT007 Following an Oral Dose of
10mg/Kg.
PK Parameters (Units)

Mean ± SD

Mean ± SD

NCA

1- Compartment

Route of Administration

Oral (n=5)

Oral (n=5)

N

5

5

Dose

10 mg/kg

10 mg/kg

Cmax (ng/mL)

83.84 ± 14.38

76.4 ± 20.4

T1//2ka (hr)

-

0.98 ± 0.34

T1/2 (hr)

2.35±0.62

2.10 ± 0.72

AUC0-∞ (hr.ng/mL)

451.01 ± 116.92

445.9 ± 126.4

Cl/F (L/hr/kg)

23.19 ± 5.23

23.73 ± 5.84

Vz/F (L/Kg)

78.60 ± 25.05

-

Vd/F(L/kg)

-

70.25 ± 22.99

tmax

1.4 ± 0.22

1.89±0.23

F%

10.9 ±2.47
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XIC of +MRM (6 pairs): 325.000/205.000 Da ID: OJT007 from Sample 14 (Rat Jurine) of pk_urine_met.wiff (Turbo Spray)

Max. 1.0e6 cps.
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Figure 42. Representative MRM chromatogram of rat plasma urine sample at 24 hours.
Peak eluting at 1.4 minutes is OJT007 glucuronide.
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4.10.2 Drug Interaction Studies Following Co-administration of OJT007 and
Rabeprazole
We conducted in vitro studies that indicated drug instability under acidic
conditions. This raised the question of whether gastric degradation could contribute to
drug loss prior to absorption in GI mucosa. Thus, to determine the effect of gastric fluids
under fasting conditions on the absorption of OJT007, the AUC of rats treated with and
without rabeprazole was assessed.
Determination of Gastric pH
The reported fasting gastric pH in rats ranges from 2.2-2.6 (Kosugi et al., 2015).
Treatment with rabeprazole (10mg/Kg) increased the pH of the stomach fluid (6.5-7) 30
minutes following rabeprazole administration. The high pH on the stomach was
maintained for at least 1 hour (pH 7-7.5). Two hours after rabeprazole administration, the
stomach pH decreased to 4.5-5. These results demonstrate that treatment with rabeprazole
can effectively increase the gastric pH in rats.
Evaluation of Pharmacokinetics in Rats Whose Gastric Acid Secretion was
Controlled.
Figure 43 shows the mean OJT007 plasma concentration-time profile with and
without rabeprazole pretreatment. Table 16 summarizes the pharmacokinetic parameters
obtained with and without rabeprazole. We hypothesized that given the instability at
acidic pH, the exposure would increase at raised pH. Contrary to our hypothesis,
following pretreatment with rabeprazole, statistically significant reductions in Cmax (P =
0.022) and AUC0-∞ (P = 0.011) of approximately 50% were observed compared to
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OJT007 alone. Interestingly, significant reductions in tmax (p<0.05) were observed. This
data suggests that the mechanisms driving the poor oral bioavailability for OJT007 is not
degradation in the GI tract and rather, more importantly, solubility and rapid metabolism.
High gastric pH has been shown to significantly decrease the absorption of basic
drugs which have low solubility at high pH (Mitra & Kesisoglou, 2013). According to
our in vitro studies, the solubility of OJT007 was low at high pH. Thus, it is possible that
the increased pH caused by the PPI resulted in reduced drug solubility, and this at least in
part decreased OJT007 exposure. Studies have determined that rabeprazole use does not
affect gastric emptying of drugs nor the metabolism mediated by CYPs (Kosugi et al.,
2015). Further studies are required to elucidate what mechanism drives the decreased
exposure.
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Figure 43. Mean OJT007 plasma concentration-time profile with and without
rabeprazole pretreatment.
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Table 16. OJT007 Pharmacokinetics With and Without PH Modulator.
PK Parameter

Cmax
(ng/mL)
AUC0-last
(ng.hr/mL)
AUC0-∞
(ng.hr/mL)
Tmax
(hr)

OJT007

OJT007+Rab

% Change

Mean

SD

Mean

SD

418

149.32

184.3

65.94

44.10

1880.40

499.19

803.59

317.65

42.73

1973.37

463.36

848.63

319.71

43.00

3.5

1.91

2.13

0.629

60.71

CHAPTER 5
SUMMARY AND CONCLUSION
OJT007 was identified as a methionine aminopeptidase inhibitor with potent
activity against L. major, the causative agent of cutaneous leishmaniasis. Early
assessment of the calculated physicochemical properties of OJT007 suggested that
OJT007 would likely be orally active. In this work, preclinical studies were conducted to
evaluate the feasibility of OJT007 becoming an oral chemotherapeutic for the treatment
of cutaneous leishmaniasis.
Bioanalytical assays are essential throughout drug development. Certainly,
preclinical development studies rely on accurate and precise quantification of the drug.
Thus, our first aim was to develop and validate a sensitive, specific, and reproducible LCMS/MS method for the quantification of OJT007 in plasma and urine. The method was
accurate, precise, and linear in the concentration range of 5-1000 ng/mL and 10-1000
ng/mL for plasma and urine, respectively. This method was successfully applied to the
biological samples obtained from the in-vivo studies. Furthermore, a UPLC-UV method
was developed for the quantification of experiments conducted in buffers.
An important prerequisite for conducting animal studies is to have a suitable
formulation of the drug. Therefore, we conducted pre-formulation studies to evaluate
OJT007 basic physicochemical properties. These studies showed OJT007 is practically
insoluble in water but soluble in DMSO and other common solvents.
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Nonetheless, the solubility slightly increases under acidic conditions. On the other
hand, our studies also highlighted the instability of OJT007 under acidic conditions,
which raised the question of whether gastrointestinal conditions could potentially affect
the exposure of orally administered OJT007. In addition, OJT007 is highly bound to
plasma proteins. These properties were used for the development of a suitable
formulation for in-vivo studies. A formulation comprised of 5% DMSO, 10% Tween 80,
20% PEG 400 and 65% Normal saline or water with a final concentration of 2.5 mg/mL
OJT007 was found to be optimal for studies.
In vitro drug metabolism studies showed that CYP450 mediated metabolism was
not a very important pathway for OJT007. On the other hand, OJT007 was rapidly
glucuronidated in liver microsomes. Initial rates of glucuronidation were similar in the
liver and intestine. The rapid glucuronidation of OJT007 may have important
implications in the in vivo disposition and bioavailability of OJT007. Furthermore, in a
comparison of initial rates of glucuronidation in human and rat liver microsome, it was
found that glucuronidation was slower in human microsomes, suggesting that metabolism
mediated by UGTs may be species-specific. Further studies are required to compare
metabolism kinetics across different species to select a suitable animal model for
toxicokinetic studies.
The oral bioavailability of OJT007 was evaluated in a crossover study design
using rats as an animal model. Following intravenous administration, OJT007 has a
biexponential disposition with a rapid distribution followed by a slower elimination. The
volume of distribution for OJT007 was larger than total body water in rats, possibly due
to partition into tissue. The mean systemic clearance of OJT007 approximated liver blood
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flow. The extraction ratio of OJT007, calculated as the ratio of systemic clearance to liver
blood, was 0.69, suggesting that OJT007 is a moderate to high extraction ratio drug.
Likewise, less than 1% of the dose was recovered unchanged in urine, suggesting
OJT007 is extensively metabolized.
Following a week washout period, the pharmacokinetics after oral administration
of OJT007 were evaluated. OJT007 has an oral bioavailability of 10.92%. Likewise, less
than 1% of the dose was recovered unchanged in urine. Assuming OJT007 to be
completely absorbed and only metabolized by the liver, the expected oral bioavailability
would be 31%. The lower-than-expected bioavailability would indicate that the drug is
not completely absorbed and/or is metabolized in the gut. Our in vitro studies suggested
an implication of intestinal UGTs in the metabolism of OJT007. Further studies are
warranted to assess the gastrointestinal permeability of OJT007 to evaluate its potential
role in bioavailability.
Since our in vitro stability studies showed a steep degradation for OJT007 under
acidic conditions, we conducted an in-vivo study in which we controlled gastric secretion
using the proton pump inhibitor rabeprazole. Contrary to our hypothesis, studies showed
that increasing the gastric pH did not increase exposure but rather the opposite. Based on
our solubility studies, it is possible that the increased pH decreased the solubility of the
drug. For drugs to be absorbed, they must be in solution as a prerequisite. Thus, gastric
acid pH did not negatively affect bioavailability. The results from our study suggest that
low solubility and extensive metabolism may be major contributors to OJT007 low
bioavailability.
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In summary, bioanalytical assays were developed for the quantification of
OJT007 in relevant biological matrices. A suitable formulation was developed for
conducting animal studies. The in vitro metabolism of OJT007 was evaluated in liver
microsomes. The pharmacokinetic profile of OJT007 in adult male SD rats was
characterized. The effect of gastric secretion on exposure was evaluated. Essentially, our
ADME evaluations demonstrated that exposure was limited by an interplay of extensive
metabolism and low solubility. These studies will be invaluable to the further
development of OJT007 as a drug for the oral treatment of cutaneous leishmaniasis.
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